Got any suggestions?
We want to hear from you! Send us a message and help improve Slidesgo
Top searches
Trending searches
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/22536203/sketchnotes-lesson1655996766.jpg)
![](http://farmaciacoslada.online/777/templates/cheerup1/res/banner1.gif)
free template
97 templates
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/15760576/digital-divide-infographics1640673400.jpg)
digital footprint
17 templates
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/41765894/welcome-to-class-for-pre-k1696257078.jpg)
welcome back
90 templates
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/39117931/minimalist-business-slides1691669242.jpg)
103 templates
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/34117148/launch-product-crowdfunding-pitch-deck1681813883.jpg)
business pitch
696 templates
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://media.slidesgo.com/storage/34888012/pulmonary-edema-treatment-breakthrough1683108248.jpg)
11 templates
Coronavirus Presentation templates
Raise awareness about one of the hottest topics of the 21st century by downloading and editing our free ppt templates and google slides themes about coronavirus..
![powerpoint presentation for coronavirus COVID-19 High School Lesson presentation template](https://media.slidesgo.com/storage/2390393/covid-19-high-school-lesson1612269073.png)
It seems that you like this template!
Premium template.
Unlock this template and gain unlimited access
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://slidesgo.com/images/illustrations/premium-creativity.png)
Register for free and start downloading now
Covid-19 high school lesson.
It's true that COVID-19 has been around for almost a year now, but it's never too late to explain all about this virus and the prevention measures. This new template will be useful for high schools, as it's been designed with an educational purpose in mind. With a color palette...
![powerpoint presentation for coronavirus The Omicron Variant Medical Infographics presentation template](https://media.slidesgo.com/storage/56856391/the-omicron-variant-medical-infographics1721381812.jpg)
The Omicron Variant Medical Infographics
Download the The Omicron Variant Medical Infographics template for PowerPoint or Google Slides and discover the power of infographics. An infographic resource gives you the ability to showcase your content in a more visual way, which will make it easier for your audience to understand your topic. Slidesgo infographics like...
![powerpoint presentation for coronavirus Rare Diseases Clinical Cases: Balantidiasis presentation template](https://media.slidesgo.com/storage/55836029/rare-diseases-clinical-cases-balantidiasis1718884138.jpg)
Rare Diseases Clinical Cases: Balantidiasis
Download the Rare Diseases Clinical Cases: Balantidiasis presentation for PowerPoint or Google Slides. A clinical case is more than just a set of symptoms and a diagnosis. It is a unique story of a patient, their experiences, and their journey towards healing. Each case is an opportunity for healthcare professionals...
![powerpoint presentation for coronavirus Omicron COVID-19 Variant Clinical Case presentation template](https://media.slidesgo.com/storage/15361858/omicron-covid-19-variant-clinical-case1639379508.jpg)
Omicron COVID-19 Variant Clinical Case
A new variant of COVID-19 has been notified by the World Health Organization and has been named "the Omicron variant". Questions and doubts start to arise and to solve them, there is no better idea than a clinical case with real examples to illustrate any doubt you may have. For...
![powerpoint presentation for coronavirus Stop The Virus! Distance Learning Escape Room presentation template](https://media.slidesgo.com/storage/4382326/stop-the-virus-distance-learning-escape-room1617110955.jpg)
Stop The Virus! Distance Learning Escape Room
If you are a fan of escape rooms you will love this template that we have created in Slidesgo. It is inspired by these games and features a virus that you have to escape from. The design is creative, with purple background, fun illustrations and sans serif typography. Go solving...
![powerpoint presentation for coronavirus COVID-19 Vaccine Breakthrough presentation template](https://media.slidesgo.com/storage/4616706/covid-19-vaccine-breakthrough1617720470.jpg)
COVID-19 Vaccine Breakthrough
Aren't you tired of COVID-19? Great news: vaccines are already here! Use this new editable template to tell your audience all the latest discoveries on the matter. Since blue is the color of safety, we've used it to set the right atmosphere. We've used other resources, such as illustrations of...
![powerpoint presentation for coronavirus Infectious Diseases Notebook presentation template](https://media.slidesgo.com/storage/54445163/infectious-diseases-notebook1716533255.jpg)
Infectious Diseases Notebook
Download the Infectious Diseases Notebook presentation for PowerPoint or Google Slides. Taking care of yourself and of those around you is key! By learning about various illnesses and how they are spread, people can get a better understanding of them and make informed decisions about eating, exercise, and seeking medical...
![powerpoint presentation for coronavirus COVID-19 Vaccine Breakthrough: Case Investigation and Reporting presentation template](https://media.slidesgo.com/storage/12281391/covid-19-vaccine-breakthrough-case-investigation-and-reporting1634202085.jpg)
COVID-19 Vaccine Breakthrough: Case Investigation and Reporting
The COVID-19 vaccine has improved the pandemic situation. We are gradually returning to our pre-COVID-19 lifestyle. All this has been achieved thanks to the enormous efforts of the scientific community, which has not rested until a remedy has been found. However, new variants of COVID-19 continue to emerge and we...
![powerpoint presentation for coronavirus Medicine and Healthcare Thesis: A Scientific Explanation of COVID-19 and its Epidemiology presentation template](https://media.slidesgo.com/storage/56257279/medicine-and-healthcare-thesis-a-scientific-explanation-of-covid-19-and-its-epidemiology1719930131.jpg)
Medicine and Healthcare Thesis: A Scientific Explanation of COVID-19 and its Epidemiology
Download the Medicine and Healthcare Thesis: A Scientific Explanation of COVID-19 and its Epidemiology presentation for PowerPoint or Google Slides. Taking care of yourself and of those around you is key! By learning about various illnesses and how they are spread, people can get a better understanding of them and...
![powerpoint presentation for coronavirus Norwalk Virus Clinical Case presentation template](https://media.slidesgo.com/storage/19600951/norwalk-virus-clinical-case1649333890.jpg)
Norwalk Virus Clinical Case
The best way to understand a disease is through a clinical case. Your knowledge about Norwalk virus, which causes acute gastroenteritis, occurs in outbreaks and is easily transmitted, will be key to prevent it. And this template, with its modern, yet professional and functional design, will be your best ally...
![powerpoint presentation for coronavirus HIV Disease Infographics presentation template](https://media.slidesgo.com/storage/54171058/hiv-disease-infographics1716270557.jpg)
HIV Disease Infographics
Download the HIV Disease Infographics template for PowerPoint or Google Slides and discover the power of infographics. An infographic resource gives you the ability to showcase your content in a more visual way, which will make it easier for your audience to understand your topic. Slidesgo infographics like this set...
![powerpoint presentation for coronavirus Yellow Fever Breakthrough presentation template](https://media.slidesgo.com/storage/54639090/yellow-fever-breakthrough1716873774.jpg)
Yellow Fever Breakthrough
Download the Yellow Fever Breakthrough presentation for PowerPoint or Google Slides.Treating diseases involves a lot of prior research and clinical trials. But whenever there’s a new discovery, a revolutionary finding that opens the door to new treatments, vaccines or ways to prevent illnesses, it’s great news. Should there be a...
![powerpoint presentation for coronavirus COVID-19 Explained for Middle School presentation template](https://media.slidesgo.com/storage/2479635/covid-19-explained-for-middle-school1612471000.png)
COVID-19 Explained for Middle School
The pandemic has completely changed the way we live. The youngest have had to adapt without understanding what was going on. If you want to make COVID-19 understandable for your middle school students, we recommend using this editable template from Slidesgo. With it you can explain the symptoms, prevention measures,...
![powerpoint presentation for coronavirus Mosquito Diseases: West Nile Virus presentation template](https://media.slidesgo.com/storage/56129304/mosquito-diseases-west-nile-virus1719553779.jpg)
Mosquito Diseases: West Nile Virus
Download the Mosquito Diseases: West Nile Virus presentation for PowerPoint or Google Slides. Taking care of yourself and of those around you is key! By learning about various illnesses and how they are spread, people can get a better understanding of them and make informed decisions about eating, exercise, and...
![powerpoint presentation for coronavirus Flu vs. COVID-19 Infographics presentation template](https://media.slidesgo.com/storage/13588504/flu-vs-covid-19-infographics1636368414.jpg)
Flu vs. COVID-19 Infographics
How to tell the difference between the flu and other diseases such as COVID-19? Some of their symptoms are similar, so we think a lot of healthcare workers will agree that people should be informed about this. Help patients or society in general by using these editable infographics. The variety...
![powerpoint presentation for coronavirus COVID-19 Outbreak Thesis presentation template](https://media.slidesgo.com/storage/2654337/covid-19-outbreak-thesis1613027001.png)
COVID-19 Outbreak Thesis
Several fields of study can benefit from interesting dissertations on how COVID-19 has spread all around the world. Your thesis is about this matter and you need to defend it in front of the assessment committee? Use this presentation during your speech and have your data on the screen while...
![powerpoint presentation for coronavirus National Influenza Vaccination Week presentation template](https://media.slidesgo.com/storage/27110029/national-influenza-vaccination-week1667381608.jpg)
National Influenza Vaccination Week
National Influenza Vaccination Week is a week in December when the importance of getting vaccinated against the flu is emphasized, especially for older people and those who are at more risk for any medical condition. Most people get through the flu just fine, but it can also have dire consequences....
- Page 1 of 10
Unsupported browser
This site was designed for modern browsers and tested with Internet Explorer version 10 and later.
It may not look or work correctly on your browser.
15 Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2024
![powerpoint presentation for coronavirus Brenda Barron](https://cms-assets.tutsplus.com/cdn-cgi/image/width=40/uploads/users/1223/profiles/19734/profileImage/192887389_10226422225921366_1386554784344850241_n.jpg)
Whether you need to make a Covid-related or any other medical presentation, one thing is certain. It’s much faster to start with a coronavirus PowerPoint template than trying to do it from scratch.
![powerpoint presentation for coronavirus covid models](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/covid_models_2022_03_07_17_17_53_utc.jpg)
Luckily, there are plenty of free and premium Covid and virus-themed PPT templates available online that you can use as a starting point.
The Best Source for COVID Coronavirus and Virus PowerPoint Templates (With Unlimited Use)
Envato Elements is the best place to find premium coronavirus, Covid, and virus PowerPoint templates with professional designs. Envato Elements is a subscription-based marketplace. It gives you access to thousands of creative assets — for a single monthly fee:
- premium PowerPoint templates for all your presentation needs
- stock photos and royalty-free music that you can use in your presentations
- fonts, icons, and more to customize your presentation
Explore Virus PowerPoint Templates Now
![powerpoint presentation for coronavirus Virus PowerPoint Templates](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/988/posts/41569/image-upload/virus_powerpoint_templates.jpg)
Envato Elements gives you the best bang for your buck if you need PowerPoint templates and other design assets regularly. Unlike our premium templates, free PowerPoint designs often lack features and customization options.
Top 5 Premium Covid and Coronavirus PowerPoint Templates From Envato Elements for 2024
Before we show you the best free PowerPoint templates with virus themes, here are the top premium coronavirus PowerPoint templates from Envato Elements:
1. Delta Corona Virus PowerPoint Template
![powerpoint presentation for coronavirus Delta Corona Virus PowerPoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/Delta_Coronavirus_PPT.jpg)
First, we've got the Delta Corona Virus PowerPoint template with a modern and clean design. This Covid slides template features 80+ slides. They've got all the necessary content ideas for you to create an engaging presentation.
The template also comes with handmade infographic elements. It was designed in HD resolution and comes in dark and light versions.
2. Covid-19 Virus - Medical PowerPoint Template
![powerpoint presentation for coronavirus Covid-19 Virus Medical PowerPoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/Covid_19_PPT_Template.jpg)
The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You’ll also find unique mockup devices, image placeholders, infographic elements, and more. The template comes in widescreen resolution.
3. Covirus - Disease & Virus PowerPoint Template
![powerpoint presentation for coronavirus Covirus Disease & Virus PowerPoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/CoVirus.jpg)
Here’s a unique and trendy Covid and virus PowerPoint template that'll make creating your presentation a breeze. The template comes with 33 unique slides. You can customize colors, fonts, and even the slide layout to create the perfect presentation. You’ll also find image and media placeholders, vector-based icons, and mockup devices.
4. Secure Virus 19 Medical PowerPoint Template
![powerpoint presentation for coronavirus Secure Virus 19 Medical Powerpoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/secure_19_virus.jpg)
This coronavirus PPT has twenty-five unique slides. It can help you deliver a comprehensive presentation. Finding the right color scheme for your business won't be a problem. Included are over ninety color schemes that are fully customizable.
You'll find much-needed infographics, vectors, and charts as well. Download this complete Covid PowerPoint template.
5. Covid Virus - Medical PowerPoint Template
![powerpoint presentation for coronavirus Covid Virus PowerPoint](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/covid_presentaiton.jpg)
This Covid presentation template gives you the power to create an eye-catching presentation. Included are forty-six slides that feature modern designs. Many graphics are included to help you deliver a compelling presentation to your audience. Free web fonts are included, and you can drag and drop in images of your choice to any slide.
The premium templates mentioned are some of the highest quality available. If you're on a budget, you may not be able to afford the premium templates. In this next section, we'll go over the top free PowerPoint templates virus.
15 Top Free Covid Coronavirus & Virus PowerPoint Templates to Download
Before looking for a free Covid PowerPoint template on the web, check Envato's free offerings first. Try out various premium template files (not always PowerPoint files) at no cost to you.
Here's the deal:
![powerpoint presentation for coronavirus Free files envato elements](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/envato_elements_free_files.png)
With that in mind, here are the best free coronavirus and virus PowerPoint templates that you can find and download online for your presentation:
1. Free Social Distance PowerPoint Template
![powerpoint presentation for coronavirus Free Social Distance Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/988/posts/41569/image-upload/free_social_distance_template.jpg)
With the help of this coronavirus PowerPoint template for free, you’ll have no problem explaining social distancing rules. The Covid PowerPoint template includes four pre-designed slides.
2. Medicine Health Care PowerPoint Templates
Try this medicine and healthcare PowerPoint template if you’re looking for a modern template. Use it to present all the necessary information about Coronavirus or any other medical emergency.
3. Medical Laboratory PowerPoint Templates
Here’s a free template virus that would be perfect for any type of virus research presentation. The template comes with individual slides as well as section covers. It includes 25 slides.
4. Coronavirus Pandemic PowerPoint Templates
Share important findings and information about Coronavirus or any other virus with this modern template. It comes with three master slides that you can customize.
5. Covid-19 Coronavirus PowerPoint Templates
This free Covid PowerPoint template has a dark green background with virus icons. Use it to quickly create a presentation. The template comes with three master slides designed in several resolutions.
![powerpoint presentation for coronavirus Covid-19 Coronavirus PowerPoint Templates](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/10_Free_Corona_Virus_PPT_Templates.jpg)
6. Infection PowerPoint Templates
Use this fun infection PowerPoint template to create a presentation about virus research or to provide more information about a specific virus. The Coronavirus PPT includes three master slides that you can duplicate to create your presentation.
7. Free COVID-19 Vaccine PowerPoint Template
With the help of this free PowerPoint template with a virus theme, you can easily share all the information people need to know about Covid-19 vaccines. The Covid vaccine theme PowerPoint comes with four slides.
8. Free COVID-19 Presentation Template
Use this Covid presentation template to create a presentation that shares information about the virus and how to fight it. The template has four master slides that you can copy as many times as you need.
9. Free Covid PowerPoint Template
Here’s a minimal and simple COVID PowerPoint template. It features an image that shows the virus spreading all over the world. It also contains four master Covid PowerPoint slides that you can copy for your presentation.
10. Free COVID PowerPoint Background
Consider this free COVID PowerPoint background for your presentation. It features an image of a word game spelling out coronavirus, pandemic, and virus.
![powerpoint presentation for coronavirus Free COVID PowerPoint Background](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/15_Free_Covid_Template.jpg)
11. Medical Illustrated. Free PowerPoint Template & Google Slides Theme
Here’s another minimal and clean PowerPoint template. Use it for any type of medical presentation. The Covid presentation template comes with 25 slides.
12. Blue Medical. Free PowerPoint Template & Google Slides Theme
The blue color in this medical and virus PowerPoint template conveys professionalism. It comes with 25 covid PowerPoint slides.
13. Medical Virus. Free PowerPoint Template & Google Slides Theme
This coronavirus PowerPoint template for free can be used for sharing information about the virus and how to prevent the spread. The template comes with 25 slides that you can duplicate, re-order, and delete as you see fit.
14. Free COVID-19 Health System Capacity Curve PowerPoint
Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations.
15. Coronavirus PowerPoint Template
Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection. It comes with several slides, including section cover and agenda slides.
![powerpoint presentation for coronavirus Coronavirus PowerPoint Template - Free](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/20_Free_Covid_Template.jpg)
How to Make a Coronavirus Presentation in PowerPoint
![powerpoint presentation for coronavirus Covilabs - Covid Medical Powerpoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/covidlabs.jpg)
1. Choose the Right Slides
Not all the slides in the template will work for your presentation. Go through each slide and pick the ones that pertain to your presentation. For the slides, you don't want to use, left-click the slide and choose Delete Slide .
![powerpoint presentation for coronavirus delete slide](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/delete_lide.jpg)
2. Add In Your Content
Now it's time to add in your presentation's content. Have a document open with all the text you want to use for each slide. Then copy and paste the text to each slide.
Each slide has text placeholders. Double-click the placeholder text and select all the text. You can then paste in your text.
![powerpoint presentation for coronavirus add in your content](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/add_in_your_content.jpg)
3. Add In Your Images
Next, we'll add in our images to make the presentation more visually appealing. Just like the text, there are also image placeholders. To add in your images, click the image icon on each slide. Your computer files pop up. Choose the image you want to add.
![powerpoint presentation for coronavirus add in image](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/add_in_image.jpg)
4. Add in Animations
To help add professional polish to your presentation, we'll add in animations. Choose the top menu header that says Animations . From there, choose the animation that you want to have on your slides. To see what each animation looks like, choose the Preview button on the far left side of the menu.
![powerpoint presentation for coronavirus animation](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1809/posts/93012/image-upload/animation.jpg)
5. Proofread Your Presentation
Often this step is skipped. We get caught up in making our design look perfect and forget to proofread our presentation. Having grammatical errors and misspelled words is the quickest way to make your presentation look unprofessional. Take the time to go over every slide in your presentation before calling it done.
5 Quick Tips To Make Virus-Themed PPT Presentations in 2024
You’ve just seen the best free and premium coronavirus slideshow templates. Now, here are a few quarantine PowerPoint ideas that'll help you design a standout presentation:
1. Stand Out With Custom Icons and Illustrations
Custom icons and illustrations make your presentation more memorable. Not to mention, they'll make your presentation stand out. The Covid-19 PowerPoint template features modern custom vector graphics that you can use as inspiration.
![powerpoint presentation for coronavirus Covid-19 PowerPoint template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/Covid_19.jpg)
2. Keep the Text to a Minimum
Don’t overwhelm your audience by adding a lot of text on your slides. This can cause them to read the slide before you’re done presenting it and they may become disengaged. Instead, keep the text to a minimum of one to three bullet points per slide.
3. Use a Professional Color Scheme
You don’t have to shy away from color in your presentation. Make sure that your color scheme is professional and doesn’t contain any clashing colors. You can draw inspiration from this modern Coronavirus Medical PowerPoint template from Envato Elements.
![powerpoint presentation for coronavirus Coronavirus Medical PowerPoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/Coronavirus.jpg)
4. Use Charts for Complex Data and Statistics
If you've got a lot of complex data and statistics, consider using charts and infographic elements to represent them. This will make it easier for your audience to understand and absorb the information.
5. Customize the Slides With Your Photos
Using stock photos is a great way to make your presentation more memorable. But you can achieve an even better effect by including photos of you, your team, and your employees. A template like the Corona Virus PowerPoint Template has plenty of image placeholders for you to use.
![powerpoint presentation for coronavirus Corona Virus PowerPoint Template](https://cms-assets.tutsplus.com/cdn-cgi/image/width=850/uploads/users/1223/posts/41569/image-upload/Corona_Virus.jpg)
Discover More Top PowerPoint Template Designs
If you want to see even more PowerPoint template examples or if you need to create a different type of presentation, look at the following template roundups:
![powerpoint presentation for coronavirus](https://cms-assets.tutsplus.com/cdn-cgi/image/width=400/uploads/users/2777/posts/28833/preview_image/preview_best_powerpoint_copy.jpg)
Common PowerPoint Questions Answered (FAQ)
If you're creating a Coronavirus PPT presentation and you're not familiar with PowerPoint, you may have some questions. We've got you covered! Here are some common PowerPoint questions and their answers:
1. I'm New to PowerPoint, What Should I Know?
PowerPoint is a powerhouse presentation software. But learning just the basics of the software enables you to create a complete presentation. Check out our ultimate PowerPoint guide to learn these basics.
2. How Should I Design My Slides?
The visual hierarchy of the slides dictates the design. The arrangement of the elements on your page and how they're placed has the biggest effect on what your audience remembers. Your slide's colors, typography, and images used are major contributors to the design of your slides.
![powerpoint presentation for coronavirus](https://cms-assets.tutsplus.com/cdn-cgi/image/width=400/uploads/users/988/posts/28172/preview_image/Preview-Image-Presentation-Design-Slides-Customized.jpg)
3. Can I Collaborate on One Presentation?
PowerPoint Online makes collaboration possible. This makes it easy to delegate separate tasks that need to be completed for the presentation. For an in-depth guide on how to collaborate as a team, view the article below.
![powerpoint presentation for coronavirus](https://cms-assets.tutsplus.com/cdn-cgi/image/width=400/uploads/users/151/posts/29630/preview_image/collaborate-pptx.jpg)
4. What Colors Should I Use In My Coronavirus PPT?
The colors that work well are blue and red. Red helps highlight the urgency and danger of the virus and blue helps build trust with your audience. If your business has a set of brand colors, then you can use these colors as well.
5. Can I Print Out My Slides?
Yes, you can! Print out your slides may be necessary depending on where you're presenting. Check out the tutorial below for a complete guide on how to print out your slides.
![powerpoint presentation for coronavirus](https://cms-assets.tutsplus.com/cdn-cgi/image/width=400/uploads/users/151/posts/29579/preview_image/print-pptx.jpg)
Learn More About Making Great PowerPoint Presentations in 2024
The tips we shared above are only a small selection of what makes a great presentation. If you want to learn more about designing and writing great PowerPoint presentations , check out the tutorials below:
![powerpoint presentation for coronavirus](https://cms-assets.tutsplus.com/cdn-cgi/image/width=400/uploads/users/26/posts/19541/preview_image/preview-powerpoint-fundamentals.png)
Create a Coronavirus Presentation Quickly With Templates
If you need to create a presentation about Coronavirus or any other type of medical presentation, there's no shortage of free PowerPoint templates with a virus theme to choose from. But, if you want to make your presentation look more unique, don’t forget to check out premium templates.
Stop by Envato Elements if you know you’ll be needing PowerPoint templates and other creative assets on the regular or if you've got multiple brands to promote.
Editorial Note: This post has been updated with contributions from Daniel Strongin . Daniel is a freelance instructor for Envato Tuts+.
![powerpoint presentation for coronavirus Brenda Barron](https://cms-assets.tutsplus.com/cdn-cgi/image/width=64/uploads/users/1223/profiles/19734/profileImage/192887389_10226422225921366_1386554784344850241_n.jpg)
- Fact sheets
- Facts in pictures
- Publications
- Questions and answers
- Tools and toolkits
- Endometriosis
- Excessive heat
- Mental disorders
- Polycystic ovary syndrome
- All countries
- Eastern Mediterranean
- South-East Asia
- Western Pacific
- Data by country
- Country presence
- Country strengthening
- Country cooperation strategies
- News releases
- Feature stories
- Press conferences
- Commentaries
- Photo library
- Afghanistan
- Cholera
- Coronavirus disease (COVID-19)
- Greater Horn of Africa
- Israel and occupied Palestinian territory
- Disease Outbreak News
- Situation reports
- Weekly Epidemiological Record
- Surveillance
- Health emergency appeal
- International Health Regulations
- Independent Oversight and Advisory Committee
- Classifications
- Data collections
- Global Health Estimates
- Mortality Database
- Sustainable Development Goals
- Health Inequality Monitor
- Global Progress
- Data collection tools
- Global Health Observatory
- Insights and visualizations
- COVID excess deaths
- World Health Statistics
- Partnerships
- Committees and advisory groups
- Collaborating centres
- Technical teams
- Organizational structure
- Initiatives
- General Programme of Work
- WHO Academy
- Investment in WHO
- WHO Foundation
- External audit
- Financial statements
- Internal audit and investigations
- Programme Budget
- Results reports
- Governing bodies
- World Health Assembly
- Executive Board
- Member States Portal
- Publications /
Tool 4. Presentation template - 28 April 2021
![powerpoint presentation for coronavirus Background Image](https://slideuplift.com/wp-content/uploads/2024/04/Login-PopUp-Side-Image.png)
One Time Code
< Go back to Login
Forgot Password
Please enter your registered email ID. You will receive an email message with instructions on how to reset your password.
![powerpoint presentation for coronavirus SlideUpLift](https://slideuplift.com/wp-content/uploads/2024/01/sitelogo.png)
COVID(Coronavirus)-19 Impact PowerPoint Template
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://slideuplift.com/wp-content/uploads/2024/05/adobe-illustrator.png)
Product Description:
Download the Free COVID-19 Impact PowerPoint presentation to share with your senior management and customers. COVID-19 has impacted businesses massively. Many of us are at a point in reviewing what it all means in the short and long run. To help you build business reviews and have key discussions, we have created a PowerPoint presentation for you to download and use. This is draft material and will be updated frequently. We are making it available free of cost as a small gesture from our side.
You can also view a COVID-19 Business Impact Presentation to get ideas to showcase its impact on the business.
Check out more Change Management templates and COVID-19 Templates .
![powerpoint presentation for coronavirus powerpoint presentation for coronavirus](https://slideuplift.com/wp-content/uploads/2024/02/Shopping-cart.png)
![](http://farmaciacoslada.online/777/templates/cheerup1/res/banner1.gif)
You May Also Like
- Covid 19 Timeline 02 - 4x3 – $4.99
- Covid 19 Timeline 02 - 16x9 – $4.99
![Covid 19 Timeline 02 PowerPoint Template & Google Slides Theme Covid 19 Timeline 02 PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/Covid-19-Timeline-02-PowerPoint-Template-297223-768x432.jpg)
Covid 19 Timeline 02 PowerPoint Template
Covid 19 Timeline 02 Presentation Template Use this Covid 19 Timeline 02 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Covid 19 Timeline 02 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- COVID-19 Global Update Dashboard - 4x3 – $4.99
- COVID-19 Global Update Dashboard - 16x9 – $4.99
![COVID-19 Global Update Dashboard PowerPoint Template & Google Slides Theme COVID-19 Global Update Dashboard PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/ItemID6428-768x576.jpg)
COVID-19 Global Update Dashboard PowerPoint Template
COVID-19 Global Update Dashboard Presentation Template Use this COVID-19 Global Update Dashboard PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID-19 Global Update Dashboard PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- COVID 19 Timeline 01 - 4x3 – $4.99
- COVID 19 Timeline 01 - 16x9 – $4.99
![COVID 19 Timeline 01 PowerPoint Template & Google Slides Theme COVID 19 Timeline 01 PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/COVID-19-Timeline-01-PowerPoint-Template-297221-768x432.jpg)
COVID 19 Timeline 01 PowerPoint Template
COVID 19 Timeline 01 Presentation Template Use this COVID 19 Timeline 01 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID 19 Timeline 01 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- COVID-19 Dashboard Global - 4x3 – $4.99
- COVID-19 Dashboard Global - 16x9 – $4.99
![COVID-19 Dashboard Global PowerPoint Template & Google Slides Theme COVID-19 Dashboard Global PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/ItemID6429-768x576.jpg)
COVID-19 Dashboard Global PowerPoint Template
COVID-19 Dashboard Global Presentation Template Use this COVID-19 Dashboard Global PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID-19 Dashboard Global PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique... read more
- Contact-Tracing-PowerPoint-Template - 4x3 – $4.99
- Contact-Tracing-PowerPoint-Template - 16x9 – $4.99
![Contact Tracing PowerPoint Template & Google Slides Theme Contact Tracing PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2022/03/Contact-Tracing-PowerPoint-Template-491042-768x432.jpg)
Contact Tracing PowerPoint Template
Contact Tracing Presentation Template Use this Contact Tracing PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Contact Tracing PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique set of editable... read more
- COVID 19 Business Impact Presentation - 4x3 – $19.99
- COVID 19 Business Impact Presentation - 16x9 – $19.99
![COVID-19 Business Impact Presentation PowerPoint Template & Google Slides Theme COVID-19 Business Impact Presentation PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/edd/2021/03/COVID-19-Business-Impact-Presentation.jpg)
COVID-19 Business Impact Presentation PowerPoint Template
About COVID-19 Business Impact Presentation PowerPoint Template The recent coronavirus pandemic has forced many businesses and industries to stop their activities until society can resume a normal life. As a result, most nations are seeing an economic impact. Businesses are the ones who have suffered a lot due to this outbreak. Our Covid-19 Business Impact Presentation PowerPoint template can help... read more
- Change Impact Matrix Template - 4x3 – $4.99
- Change Impact Matrix Template - 16x9 – $4.99
![Change Impact Matrix PowerPoint Template & Google Slides Theme Change Impact Matrix PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/Change-Impact-Matrix-PowerPoint-Template-119684-768x432.png)
Change Impact Matrix PowerPoint Template
Change Impact Matrix Presentation Template Use this Change Impact Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Impact Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique... read more
- Covid-19-Timeline-05 - 4x3 – $4.99
- Covid-19-Timeline-05 - 16x9 – $4.99
![COVID-19 Timeline Template for PowerPoint and Google Slides 05 Theme COVID-19 Timeline Template for PowerPoint and Google Slides 05 Theme](https://slideuplift.com/wp-content/uploads/2024/04/Covid-19-Timeline-05-PowerPoint-Template-332843-768x432.jpg)
COVID-19 Timeline Template for PowerPoint and Google Slides 05
COVID-19 Timeline Template for PowerPoint and Google Slides 05 The Covid-19 Timeline Template shows the timeline of Covid-19 symptoms and treatments over 22 days. The timeline shows the days from day 01 to day 22, making it clear how symptoms and treatments change over time. On the left side of the slide, there is a column where different symptoms are... read more
![arrowleft arrowleft](https://slideuplift.com/wp-content/uploads/2024/01/arrowleft.png.webp)
Recommended for you
- Change Impact Assemment Matrix - 4x3 – $6.99
- Change Impact Assemment Matrix - 16x9 – $6.99
![Change Impact Assemment Matrix PowerPoint Template & Google Slides Theme Change Impact Assemment Matrix PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/Change-Impact-Assemment-Matrix-PowerPoint-Template-119683-768x432.png)
Change Impact Assemment Matrix PowerPoint Template
Change Impact Assessment Matrix Presentation Template Use this Change Impact Assessment Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Impact Assessment Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- Covid 19 Timeline 04 - 4x3 – $6.99
- Covid 19 Timeline 04 - 16x9 – $6.99
![COVID-19 Timeline Template for PowerPoint and Google Slides 04 Theme COVID-19 Timeline Template for PowerPoint and Google Slides 04 Theme](https://slideuplift.com/wp-content/uploads/2024/04/Covid-19-Timeline-04-PowerPoint-Template-297326-768x432.jpg)
COVID-19 Timeline Template for PowerPoint and Google Slides 04
COVID-19 Timeline Template for PowerPoint and Google Slides 04 The COVID-19 Timeline Template is meant to track and present a timeline of important events related to the COVID-19 pandemic. It includes a timeline for key dates, milestones, and actions taken during the early stages of the outbreak. This template can be really helpful for educational, informational, or reporting purposes. The... read more
- Covid 19 Timeline 03 - 4x3 – $4.99
- Covid 19 Timeline 03 - 16x9 – $4.99
![Covid 19 Timeline 03 PowerPoint Template & Google Slides Theme Covid 19 Timeline 03 PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/Covid-19-Timeline-03-PowerPoint-Template-297225-768x432.jpg)
Covid 19 Timeline 03 PowerPoint Template
Covid 19 Timeline 03 Presentation Template Use this Covid 19 Timeline 03 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Covid 19 Timeline 03 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- COVID Business Impact Grid Matrix - 4x3 – $4.99
- COVID Business Impact Grid Matrix - 16x9 – $4.99
![COVID Business Impact Grid Matrix PowerPoint Template & Google Slides Theme COVID Business Impact Grid Matrix PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/05/COVID-Business-Impact-Grid-Matrix-PowerPoint-Template-106487-768x432.png)
COVID Business Impact Grid Matrix PowerPoint Template
COVID Business Impact Grid Matrix Presentation Template Use this COVID Business Impact Grid Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID Business Impact Grid Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey... read more
- Change Management KPI Metrics - 4x3 – $6.99
- Change Management KPI Metrics - 16x9 – $6.99
![Change Management KPI Metrics PowerPoint Template & Google Slides Theme Change Management KPI Metrics PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/06/Change-Management-KPI-Metrics-PowerPoint-Template-133318-768x432.png)
Change Management KPI Metrics PowerPoint Template
Change Management KPI Metrics Presentation Template Use this Change Management KPI Metrics PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Management KPI Metrics PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
![2 Steps Business 1 PowerPoint Template & Google Slides Theme 2 Steps Business 1 PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/edd/2020/07/2-Steps-Business-PowerPoint-Template-1-4x3-1-768x576.jpg)
2 Steps Business 1 PowerPoint Template
Free 2 Steps Business 1 Presentation Template Use this Free 2 Steps Business 1 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Free 2 Steps Business 1 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey... read more
![Business Steps 8 PowerPoint Template & Google Slides Theme Business Steps 8 PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/edd/2020/09/5-ItemID-2542-Business-Steps-PowerPoint-Template-8-4x3_r_7_7-768x576.jpg)
Business Steps 8 PowerPoint Template
Free Business Steps 8 Presentation Template Use this Free Business Steps 8 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Free Business Steps 8 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
- Change Managment Business Framework - 4x3 – $4.99
- Change Managment Business Framework - 16x9 – $4.99
![Change Managment Business Framework PowerPoint Template & Google Slides Theme Change Managment Business Framework PowerPoint Template & Google Slides Theme](https://slideuplift.com/wp-content/uploads/2020/09/Change-Managment-Business-Framework-PowerPoint-Template-189903-768x432.png)
Change Managment Business Framework PowerPoint Template
Change Management Business Framework Presentation Template Use this Change Management Business Framework PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Management Business Framework PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly... read more
Forgot Password?
Join the SlideUpLift Discount Club- A Lifetime Value
![powerpoint presentation for coronavirus club](https://slideuplift.com/wp-content/themes/olam-child/img/club_logo.png)
Benefits never expire and apply to the whole SlideUplift library including future additions.
Upon paying a one time fee, you will remain a Discount Clubber for a lifetime and enjoy 20% discounts on all products that you purchase à la carte from SlideUpLift.com
Privacy Overview
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
![powerpoint presentation for coronavirus www.crystalgraphics.com](https://powerpoint.crystalgraphics.com/themes/crystal/images/new_cg_logo.jpg)
- Ultimate Combo
![powerpoint presentation for coronavirus shopping cart](https://powerpoint.crystalgraphics.com/themes/crystal/images/shopping_cart_gray_90x90.png)
- Sign Out Sign Out Sign In
![powerpoint presentation for coronavirus search icon](https://powerpoint.crystalgraphics.com/themes/crystal/images/search-icon-8.5.png)
221 Best Covid-Themed Templates for PowerPoint & Google Slides
With over 6 million presentation templates available for you to choose from, crystalgraphics is the award-winning provider of the world’s largest collection of templates for powerpoint and google slides. so, take your time and look around. you’ll like what you see whether you want 1 great template or an ongoing subscription, we've got affordable purchasing options and 24/7 download access to fit your needs. thanks to our unbeatable combination of quality, selection and unique customization options, crystalgraphics is the company you can count on for your presentation enhancement needs. just ask any of our thousands of satisfied customers from virtually every leading company around the world. they love our products. we think you will, too" id="category_description">crystalgraphics creates templates designed to make even average presentations look incredible. below you’ll see thumbnail sized previews of the title slides of a few of our 221 best covid templates for powerpoint and google slides. the text you’ll see in in those slides is just example text. the covid-related image or video you’ll see in the background of each title slide is designed to help you set the stage for your covid-related topics and it is included with that template. in addition to the title slides, each of our templates comes with 17 additional slide layouts that you can use to create an unlimited number of presentation slides with your own added text and images. and every template is available in both widescreen and standard formats. with over 6 million presentation templates available for you to choose from, crystalgraphics is the award-winning provider of the world’s largest collection of templates for powerpoint and google slides. so, take your time and look around. you’ll like what you see whether you want 1 great template or an ongoing subscription, we've got affordable purchasing options and 24/7 download access to fit your needs. thanks to our unbeatable combination of quality, selection and unique customization options, crystalgraphics is the company you can count on for your presentation enhancement needs. just ask any of our thousands of satisfied customers from virtually every leading company around the world. they love our products. we think you will, too.
Widescreen (16:9) Presentation Templates. Change size...
![powerpoint presentation for coronavirus Presentation with covid - Colorful theme enhanced with portrait-of-african-girl-wearing backdrop and a light gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/portrait-of-african-girl-wearing_bycadeaday_6.5_ws.jpg)
Theme enhanced with portrait of african girl wearing face mask and writing solution of sums on white board at school black schoolgirl solving addition sum on white board during covid-19 pandemic school child thinking
![powerpoint presentation for coronavirus Presentation with covid - Colorful presentation theme enhanced with senior-lady-praying-with-face backdrop and a ocean colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/senior-lady-praying-with-face_bxaxfyxgzy_6.5_ws.jpg)
Presentation theme enhanced with senior lady praying with face mask reading the bible in front of a church in covid-19 times
![powerpoint presentation for coronavirus Presentation with covid - Slide deck having back-to-school-during-covid background and a tawny brown colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/back-to-school-during-covid_bxzccaycdb_6.5_ws.jpg)
Slide deck having back to school during covid pandemics teacher with face mask
![powerpoint presentation for coronavirus Presentation with covid - Theme featuring back-to-school-concept-during background and a dark gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/back-to-school-concept-during_byaaegcyex_6.5_ws.jpg)
Theme featuring back to school concept during covid - pile of books and medical mask
![powerpoint presentation for coronavirus Presentation with covid - Audience pleasing slides consisting of doctor-wearing-safety-protective-mask backdrop and a teal colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/doctor-wearing-safety-protective-mask_byfcygcabe_6.5_ws.jpg)
Slides consisting of doctor wearing safety protective mask supporting and cheering up senior patient during home visit during covid-19 pandemic nurse and old woman wearing facemasks during coronavirus and flu outbreak
![powerpoint presentation for coronavirus Presentation with covid - Slides with lovely-granddaughter-walking-with-senior background and a gold colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/lovely-granddaughter-walking-with-senior_byfcygcaaf_6.5_ws.jpg)
Slides with lovely granddaughter walking with senior woman in park and wearing face mas against covid-19 smiling old grandmother with happy caregiver in park relaxing after quarantine due to coronavirus background
![powerpoint presentation for coronavirus Presentation with covid - Slide set consisting of female-scientist-working-in-modern background and a teal colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/female-scientist-working-in-modern_bgyxbbdxzz_6.5_ws.jpg)
Slide set consisting of female scientist working in modern lab doctor making microbiology research laboratory tools microscope test tubes equipment coronavirus covid-19 bacteriology virology dna and health care
![powerpoint presentation for coronavirus Presentation with covid - Slide deck consisting of confident-multiethnic-male-nurse background and a light blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/confident-multiethnic-male-nurse_bzegcedbxz_6.5_ws.jpg)
Slide deck consisting of confident multiethnic male nurse in front of his medical team looking at camera wearing face mask during covid-19 outbreak happy and proud indian young surgeon standing in front of his colleagues
![powerpoint presentation for coronavirus Presentation with covid - Beautiful presentation design featuring exhausted-nurse-on-duty backdrop and a light blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/exhausted-nurse-on-duty_byyzebgyyc_6.5_ws.jpg)
Presentation design featuring exhausted nurse on duty in the emergency room of a clinic with coronavirus and covid-19 pandemic
![powerpoint presentation for coronavirus Presentation with covid - Slide deck having smiling-nurse-with-face-mask background and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/smiling-nurse-with-face-mask_bzeaxxdfzb_6.5_ws.jpg)
Slide deck having smiling nurse with face mask helping senior woman to walk around the nursing home with walker young lovely nurse helping old woman with surgical mask for safety against covid-19 using a walking frame
![powerpoint presentation for coronavirus Presentation with covid - Cool new presentation theme with closeup-of-a-man-wearing backdrop and a cobalt blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/closeup-of-a-man-wearing_bzaddbzafa_6.5_ws.jpg)
Presentation theme with closeup of a man wearing blue surgical gloves placing the sample into the covid-19 antigen diagnostic test device on a blue surface
![powerpoint presentation for coronavirus Presentation with covid - Slide set enhanced with high-school-student-taking-notes background and a mint green colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/high-school-student-taking-notes_bycbegexfd_6.5_ws.jpg)
Slide set enhanced with high school student taking notes while wearing face mask due to coronavirus emergency young woman sitting in class with their classmates and wearing surgical mask due to covid-19 pandemic
![powerpoint presentation for coronavirus Presentation with covid - Presentation theme enhanced with doctor-giving-a-senior-woman background and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/doctor-giving-a-senior-woman_bygyyzycfd_6.5_ws.jpg)
Presentation theme enhanced with doctor giving a senior woman a vaccination virus protection covid-2019 background
![powerpoint presentation for coronavirus Presentation with covid - Cool new PPT layouts with surface-sanitizing-against-covid-19 backdrop and a ocean colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/surface-sanitizing-against-covid-19_bgzegfecga_6.5_ws.jpg)
PPT layouts with surface sanitizing against covid-19 outbreak home cleaning spraying antibacterial spray bottle disinfecting against coronavirus wearing nitrile gloves sanitize hospital surfaces prevention
![powerpoint presentation for coronavirus Presentation with covid - Cool new presentation design with coronavirus-success-happy-news-lab backdrop and a light blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/coronavirus-success-happy-news-lab_bxagxaaaba_6.5_ws.jpg)
Presentation design with coronavirus success happy news lab researcher doing thumbs up with medical gloves for vaccine ppe for covid-19 healthcare
![powerpoint presentation for coronavirus Presentation with covid - Cool new presentation with digital-illustration-of-a-coronavirus backdrop and a light blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/digital-illustration-of-a-coronavirus_bxcdccgbea_6.5_ws.jpg)
Presentation with digital illustration of a coronavirus covid-19 cell lying by a face mask over data processing statistics showing in the background medicine public health pandemic coronavirus covid 19 outbreak
![powerpoint presentation for coronavirus Presentation with covid - Colorful PPT theme enhanced with doctor-and-senior-man-wearing backdrop and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/doctor-and-senior-man-wearing_bgzacgxdxy_6.5_ws.jpg)
PPT theme enhanced with doctor and senior man wearing facemasks during coronavirus and flu outbreak virus and illness protection home quarantine covid-2019 backdrop
![powerpoint presentation for coronavirus Presentation with covid - Cool new PPT theme with staycation-sign-for-summer-vacation backdrop and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/staycation-sign-for-summer-vacation_bxdeyfebfa_6.5_ws.jpg)
PPT theme with staycation sign for summer vacation plans during covid-19 funny vintage hawaiian pink felt board text for staying home for the holidays what to do this summer without travel backdrop
![powerpoint presentation for coronavirus Presentation with covid - Cool new slide deck with working-from-home-remote-work backdrop and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/working-from-home-remote-work_bgzcaxgzga_6.5_ws.jpg)
Slide deck with working from home remote work inspirational social media lightbox message board next to laptop and coffee cup for covid-19 quarantine closure of all businesses
![powerpoint presentation for coronavirus Presentation with covid - Audience pleasing theme consisting of covid-19-and-the-global backdrop and a teal colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/covid-19-and-the-global_bxafagdzfe_6.5_ws.jpg)
Theme consisting of covid-19 and the global economy a modern businessman in a medical mask manages business processes using digital technology remote business backdrop
![powerpoint presentation for coronavirus Presentation with covid - PPT layouts having mixed-race-african-american-teenager background and a gold colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/mixed-race-african-american-teenager_bxebdaeydb_6.5_ws.jpg)
PPT layouts having mixed race african american teenager teen girl young woman wearing a face mask outside during the coronavirus covid-19 pandemic
![powerpoint presentation for coronavirus Presentation with covid - Presentation theme consisting of sad-asian-mature-woman-lonely background and a light gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/sad-asian-mature-woman-lonely_bgyczzfybz_6.5_ws.jpg)
Presentation theme consisting of sad asian mature woman lonely at home self isolation quarantine for covid-19 coronavirus social distancing prevention mental health anxiety depressed thinking senior chinese lady
![powerpoint presentation for coronavirus Presentation with covid - Amazing PPT theme having two-boys-wanting-to-play backdrop and a yellow colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/two-boys-wanting-to-play_bybzcagbeg_6.5_ws.jpg)
PPT theme having two boys wanting to play football in stadium during covid-19 wearing face masks backdrop
![powerpoint presentation for coronavirus Presentation with covid - Slides enhanced with back-to-school-concept-during background and a wine colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/back-to-school-concept-during_byaaegcyfd_6.5_ws.jpg)
Slides enhanced with back to school concept during covid - school utensils and medical mask on yellow background
![powerpoint presentation for coronavirus Presentation with covid - Slides with vaccine-and-syringe-injection background and a sky blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/vaccine-and-syringe-injection_bxcyygaaaf_6.5_ws.jpg)
Slides with vaccine and syringe injection for prevention immunization and treatment of coronavirus infection covid-19 ncov 2019
![powerpoint presentation for coronavirus Presentation with covid - Cool new PPT layouts with reopening-of-a-small-business backdrop and a dark gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/reopening-of-a-small-business_bxbegxgfga_6.5_ws.jpg)
PPT layouts with reopening of a small business activity after the covid-19 emergency ended the lockdown and quarantine a business sign that says now we are open support local businesses hang on door at entrance
![powerpoint presentation for coronavirus Presentation with covid - Colorful slides enhanced with doctor-wearing-facemask-and-superhero backdrop and a light gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/doctor-wearing-facemask-and-superhero_bxaycbegay_6.5_ws.jpg)
Slides enhanced with doctor wearing facemask and superhero cape during coronavirus outbreak virus and illness protection quarantine covid-2019 super hero power for medicine
![powerpoint presentation for coronavirus Presentation with covid - Amazing slide deck having washing-hands-with-soap backdrop and a soft green colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/washing-hands-with-soap_bgxfxycbdg_6.5_ws.jpg)
Slide deck having washing hands with soap and warm water for 20 seconds for corona virus covid-10 prevention work man for corona virus hygiene to stop spreading coronavirus backdrop
![powerpoint presentation for coronavirus Presentation with covid - Colorful PPT theme enhanced with businesswoman-closing-her-business-activity backdrop and a teal colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/businesswoman-closing-her-business-activity_bxbegxgfey_6.5_ws.jpg)
PPT theme enhanced with businesswoman closing her business activity due to covid-19 lockdown owner with surgical mask close the doors of her store due to quarantine coronavirus close up sign due to the effect of covid-19
![powerpoint presentation for coronavirus Presentation with covid - Cool new presentation theme with covid-19-coronavirus-outbreak-doctor backdrop and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/covid-19-coronavirus-outbreak-doctor_bxadeacaya_6.5_ws.jpg)
Presentation theme with covid-19 coronavirus outbreak doctor praying for help young woman medical nurse portrait hoping for positive future backdrop
![powerpoint presentation for coronavirus Presentation with covid - Slides consisting of covid-19-stay-home-delivering background and a seafoam green colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/covid-19-stay-home-delivering_bxcaecxfaz_6.5_ws.jpg)
Slides consisting of covid-19 stay home delivering grocery supply for elderly
![powerpoint presentation for coronavirus Presentation with covid - Cool new slide set with two-business-people-greeting backdrop and a gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/two-business-people-greeting_bxxbcdxzea_6.5_ws.jpg)
Slide set with two business people greeting at distance with their elbows as a prevention because of covid-19 backdrop
![powerpoint presentation for coronavirus Presentation with covid - PPT layouts having doctor-and-senior-man-wearing background and a light gray colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/doctor-and-senior-man-wearing_bgyxxebcgb_6.5_ws.jpg)
PPT layouts having doctor and senior man wearing facemasks during coronavirus and flu outbreak virus and illness protection home quarantine covid-2019
![powerpoint presentation for coronavirus Presentation with covid - Cool new PPT theme with happy-man-holding-an-umbrella backdrop and a teal colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/happy-man-holding-an-umbrella_bzcbgzccga_6.5_ws.jpg)
PPT theme with happy man holding an umbrella in a money rain covid coronavirus business concept
![powerpoint presentation for coronavirus Presentation with covid - PPT layouts with economic-crisis-due-to-coronavirus background and a sky blue colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/economic-crisis-due-to-coronavirus_bxcydfbzcf_6.5_ws.jpg)
PPT layouts with economic crisis due to coronavirus covid-19
![powerpoint presentation for coronavirus Presentation with covid - Slides featuring portrait-of-asian-office-employee background and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/portrait-of-asian-office-employee_byaxebcgbx_6.5_ws.jpg)
Slides featuring portrait of asian office employee businesswoman wear protective face mask work in new normal office with interracial colleague in background as social distance practice prevent coronavirus covid-19
![powerpoint presentation for coronavirus Presentation with covid - Cool new presentation with women-on-a-walk backdrop and a tawny brown colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/women-on-a-walk_bxxgdzxdxa_6.5_ws.jpg)
Presentation with women on a walk in the woods in the foreground a medical mask hanging on the branch of spruce tree life during covid-19 pandemic backdrop
![powerpoint presentation for coronavirus Presentation with covid - Beautiful PPT layouts featuring mature-manager-in-office-discussing backdrop and a coral colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/mature-manager-in-office-discussing_bzfcfyxaec_6.5_ws.jpg)
PPT layouts featuring mature manager in office discussing strategy with employees while wearing face mask during covid-19 pandemic group of multiethnic business people in meeting keeping social distancing in boardroom
![powerpoint presentation for coronavirus Presentation with covid - Amazing presentation theme having closeup-of-a-green-bookbag backdrop and a ocean colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/closeup-of-a-green-bookbag_bxycbbfyyg_6.5_ws.jpg)
Presentation theme having closeup of a green bookbag and a blue surgical mask with the text back to school written in it depicting the need to prevent the infection at school in the covid-19 pandemic situation
![powerpoint presentation for coronavirus Presentation with covid - PPT theme enhanced with little-girl-holding-her-dog background and a soft green colored foreground](https://s3.amazonaws.com/ppt-ct2.crystalgraphics.com/little-girl-holding-her-dog_bgydycxdyd_6.5_ws.jpg)
PPT theme enhanced with little girl holding her dog both wearing protective surgical masks caring about her pet performing basic protective measures against transmission of coronavirus covid-19 disease
More covid templates for powerpoint and google slides:.
![powerpoint presentation for coronavirus previous](https://powerpoint.crystalgraphics.com/themes/crystal/images/pagin-prev-gray.png)
Company Info
![powerpoint presentation for coronavirus U.S. flag](https://www.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png)
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
Pfizer COVID-19 Vaccine Summary
COMIRNATY ® and Pfizer-BioNTech COVID-19 Vaccine 2024-2025 Formula
Presentations and Indications
Ordering and return policy, storage requirements, diluent type and volume, additional information.
The following product summary can be used by product providers to prepare orders for fall and winter virus season.
- COMIRNATY (30 mcg/0.3mL glass pre-filled syringe presentation) is indicated for individuals 12 years of age and older.
- Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation).
Minimum Initial Order
When ordering vaccines directly from the company, there is no minimum initial order requirement.
Pre-ordering or Reservation Programs
The reservation platform Pfizer Prime is now open for orders of COMIRNATY (2024-25 Formula) and Pfizer-BioNTech COVID-19 Vaccine (2024-25 Formula), which are pending FDA review and approval or authorization . A nominal discount is offered to customers that place a reservation. Customers that order directly on Pfizer Prime can contact Pfizer Customer Service at 1-800-666-7248. Customers can also work with their wholesaler for details on placing reservations via the wholesaler, if preferred.
Return Policy
Unopened vaccine.
For the COMIRNATY Vaccine for individuals 12 years of age and older, customers have the option to return up to 30% of their seasonal purchases, though specific terms may apply based on individual contracts.
For Pfizer-BioNTech COVID-19 Vaccine for individuals 6 months through 11 years of age, we offer a 100% returns policy.
Opened Vaccine
Returns for opened Pfizer-BioNTech COVID-19 Vaccines for individuals 6 months through 4 years of age in multi-dose vials may be partial, depending on the estimated remaining contents of the vial.
For additional questions, please reach out to Pfizer Customer Service at 800-666-7248 .
Multi-dose and single-dose vials
The multi-dose and single-dose vials must be stored frozen at ultra-cold temperatures (between -90⁰C and -60⁰C). Once the vials are thawed, the multi-dose and single-dose vials must be stored refrigerated (between 2⁰C and 8⁰C).
Glass single-dose pre-filled syringes
The glass single-dose pre-filled syringes for ages 12 and older must be stored refrigerated (between 2⁰C and 8⁰C); DO NOT FREEZE. The total time out of refrigeration (at temperatures between 8°C and 25°C) must not exceed 12 hours.
1.1 mL of sterile 0.9% Sodium Chloride Injection, USP.
Reconstitution is required only for the Pfizer-BioNTech COVID-19 Vaccine for individuals 6 months through 4 years of age in multi-dose vials.
The CDC At-A-Glance fact sheet is currently being updated with 2024-25 information.
Shelf Life | 6 months through 4 years | 5 years through 11 years | 12 and older |
---|---|---|---|
Unopened, frozen vaccine | Once received, frozen vials may be stored in an ultra-low temperature freezer at -90ºC to -60ºC until the expiration date printed on the vials and cartons. Do not store vials at -25°C to -15°C. Once vials are thawed, they should not be refrozen. | DO NOT FREEZE. | |
Unopened, refrigerated vaccine | Once received, frozen vials may be immediately transferred to the refrigerator [2ºC to 8ºC], thawed and stored for up to 10 weeks, not to exceed the expiration date printed on the vial and cartons. If vials and cartons are received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the 10-week refrigerated expiry date, not to exceed the expiration date printed on the vial and cartons. | The vaccine may be stored at 2°C to 8°C until the expiration date printed on the carton and syringe labels (not to exceed 8 months). DO NOT FREEZE. | |
Opened, refrigerated vaccine | If not previously thawed at 2ºC to 8ºC, allow multi-dose vials or single dose vials to thaw at room temperature [up to 25ºC (77ºF)] for 30 minutes. | After removing the tip cap and attaching an appropriate needle, the glass prefilled syringe should be used immediately. If it cannot be used immediately, it must be used within 4 hours. DO NOT FREEZE. | |
Opened, room temperature vaccine | If not previously thawed at 2ºC to 8ºC, allow multi-dose vials or single dose vials to thaw at room temperature [up to 25ºC (77ºF)] for 30 minutes.
| After removing the tip cap and attaching an appropriate needle, the glass prefilled syringe should be used immediately. If it cannot be used immediately, it must be used within 4 hours. DO NOT FREEZE. |
2023-24 formula
COMIRNATY is FDA-approved for individuals 12 years of age and older.
Pfizer-BioNTech COVID-19 Vaccine is authorized by FDA for emergency use in individuals 6 months through 11 years of age. It is not licensed for any use.
2024-25 formula
The updated 2024-2025 formulas of COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine will be subject to FDA review for authorization and/or approval in the coming months.
Both COMIRNATY (2023-2024 Formula) and Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) are currently available.
The FDA provided guidance on the preferred KP.2 strain for the COVID-19 vaccines (2024-25 Formula) on June 13, 2024: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024 . The updated 2024-25 formula of COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine are pending FDA review for approval and authorization for emergency use.
For multi-dose vials for ages 6 months through 4 years of age and single-dose vials for ages 5 years through 11 years of age shipped at ultra-low temperatures, the shipping container includes a real-time temperature monitor and documentation to inform the provider how to operate the monitor and receive a quality disposition report by e-mail informing them of the viability of the product. If the product is not viable or if the provider has any questions, they should contact Pfizer Customer Service at 800-666-7248.
For glass single-dose pre-filled syringes for ages 12 and older shipped refrigerated (at 2ºC to 8ºC), the shipping container does not include a temperature monitor. These shippers are qualified to hold a specific temperature for a set period of time. Upon receipt of the shipper, the provider will see a time stamp on the package informing them of the time the product is viable. If the provider does not receive the shipment per that time stamp or if the provider has any questions, they should contact Pfizer Customer Service at 800-666-7248 .
Exit Notification / Disclaimer Policy
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
![powerpoint presentation for coronavirus Johnson & Johnson Company](https://s203.q4cdn.com/636242992/files/design/logos/JJ-Logo-Signature-PMS-Red-png_JJLogoSignaturePMS-Red.png)
Investor Relations
News Details
Johnson & johnson reports q2 2024 results.
- 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%*
- 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%*
- Significant new product pipeline progress including TREMFYA IBD and subcutaneous filings, RYBREVANT subcutaneous filing, and VARIPULSE admIRE data release
- Company increases Full-Year 2024 operational sales 5 guidance to reflect the acquisition of Shockwave Medical
- Company updates Full-Year 2024 adjusted operational EPS guidance to reflect improved performance; costs associated with recent strategic acquisitions more than offset the improvement
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth,” said Joaquin Duato, Chairman and Chief Executive Officer. “With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth.”
Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson.
Overall financial results
|
|
| |
Reported Sales | $22,447 | $21,519 | 4.3% |
Net Earnings | $4,686 | $5,376 | -12.8% |
EPS (diluted) | $1.93 | $2.05 | -5.9% |
|
|
| |
Operational Sales | 6.6% | ||
Adjusted Operational Sales | 6.5% | ||
Adjusted Operational Sales ex. COVID-19 Vaccine | 7.1% | ||
Adjusted Net Earnings | $6,840 | $6,730 | 1.6% |
Adjusted EPS (diluted) | $2.82 | $2.56 | 10.2% |
| Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |
| Excludes the impact of translational currency | |
| Excludes the net impact of acquisitions and divestitures and translational currency | |
| Excludes intangible amortization expense and special items | |
| Excludes COVID-19 Vaccine | |
Note: values may have been rounded |
Regional sales results
|
|
|
|
|
| |
|
|
|
|
|
|
|
U.S. | $12,569 | $11,657 | 7.8% | 7.8 | — | 7.6 |
International | 9,878 | 9,862 | 0.2 | 5.1 | (4.9) | 5.3 |
Worldwide | $22,447 | $21,519 | 4.3% | 6.6 | (2.3) | 6.5 |
| Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |
| Excludes the impact of translational currency | |
| Excludes the net impact of acquisitions and divestitures and translational currency | |
Note: values may have been rounded |
Segment sales results
|
|
|
|
|
| |
|
|
|
|
|
|
|
Innovative Medicine | $14,490 | $13,731 | 5.5% | 7.8 | (2.3) | 8.0 |
MedTech | 7,957 | 7,788 | 2.2 | 4.4 | (2.2) | 4.0 |
Worldwide | $22,447 | $21,519 | 4.3% | 6.6 | (2.3) | 6.5 |
Second Quarter 2024 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 8.8%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), and Other Oncology in Oncology, TREMFYA (guselkumab) and STELARA (ustekinumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by Other Neuroscience. Including the COVID-19 Vaccine, Innovative Medicine worldwide operational sales grew 7.8%*.
MedTech worldwide operational sales grew 4.4%*, with acquisitions and divestitures positively impacting growth by 0.4%. Operational sales growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.
Full-year 2024 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact for the recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
|
|
|
|
Improved performance outlook | $0.05 |
pre-M&A |
|
M&A impact | ($0.68) |
|
|
| Non-GAAP financial measure; excludes the impact of translational currency | |
| Non-GAAP financial measure; excludes intangible amortization expense and special items | |
Note: Adjusted operational EPS figures reflect midpoint of issued guidance |
|
| |
Adjusted Operational Sales Change vs. Prior Year / Mid-point | 5.5% – 6.0% / 5.8% | 5.5% – 6.0% / 5.8% |
Operational Sales / Mid-point Change vs. Prior Year / Mid-point | $89.2B – $89.6B / $89.4B 6.1% – 6.6% / 6.4% | $88.7B – $89.1B / $88.9B 5.5% – 6.0% / 5.8% |
Estimated Reported Sales / Mid-point Change vs. Prior Year / Mid-point | $88.0B – $88.4B / $88.2B 4.7% – 5.2% / 5.0% | $88.0B – $88.4B / $88.2B 4.7% – 5.2% / 5.0% |
Adjusted Operational EPS (Diluted) / Mid-point Change vs. Prior Year / Mid-point | $10.00 – $10.10 / $10.05 0.8% – 1.8% / 1.3% | $10.60 – $10.75 / $10.68 6.9% – 8.4% / 7.7% |
Adjusted EPS (Diluted) / Mid-point Change vs. Prior Year / Mid-point | $9.97 – $10.07 / $10.02 0.5% – 1.5% / 1.0% | $10.57 – $10.72 / $10.65 6.6% – 8.1% / 7.4% |
| Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures | |
| Non-GAAP financial measure; excludes the impact of translational currency | |
| Calculated using Euro Average Rate: July 2024 = $1.08 and April 2024 = $1.08 (Illustrative purposes only) | |
| Non-GAAP financial measure; excludes intangible amortization expense and special items | |
| Excludes COVID-19 Vaccine | |
Note: percentages may have been rounded |
Other modeling considerations will be provided on the webcast .
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases , as well as Innovative Medicine News Center , MedTech News & Events , www.factsabouttalc.com , and www.LLTManagementInformation.com .
| CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations |
|
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations |
| |
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of moderately to severely active Crohn’s disease |
| |
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer |
| |
DePuy Synthes Receives 510(k) FDA Clearance of the VELYS Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures |
| |
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease |
| |
CARVYKTI (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy |
| |
| CARVYKTI (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study |
|
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients |
| |
TREMFYA (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction |
| |
Johnson & Johnson showcases innovation and leadership in rheumatology at EULAR 2024 Congress |
| |
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes |
| |
Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA |
| |
TREMFYA (guselkumab) demonstrates superiority versus STELARA (ustekinumab) in Phase 3 Crohn’s disease program |
| |
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission |
| |
Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting |
| |
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively |
| |
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024 |
| |
Phase 2 data for ERLEADA (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery |
| |
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer |
| |
| Biosense Webster Launches New Version of CARTO 3 Electro-Anatomical Mapping System |
|
| Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 |
|
Johnson & Johnson Completes Acquisition of Proteologix, Inc. |
| |
Johnson & Johnson Completes Acquisition of Shockwave Medical |
| |
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis |
| |
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization |
| |
Subsequent to the quarter |
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations .
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com .
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results .
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
(Unaudited; Dollars in Millions) | |||||||||||||||||||||||||
|
|
|
| Percent Change |
|
|
|
|
| Percent Change | |||||||||||||||
|
|
|
| Total |
| Operations |
| Currency |
|
|
|
|
| Total |
| Operations |
| Currency | |||||||
Innovative Medicine | |||||||||||||||||||||||||
U.S. |
|
|
| 8.9 |
|
| 8.9 | - |
|
|
|
| 8.6 |
|
| 8.6 | - |
| |||||||
International |
|
|
| 1.1 |
| 6.4 | (5.3 | ) |
|
|
| (3.0 | ) | 1.0 | (4.0 | ) | |||||||||
|
|
|
| 5.5 |
| 7.8 | (2.3 | ) |
|
|
| 3.3 |
| 5.2 | (1.9 | ) | |||||||||
| |||||||||||||||||||||||||
Innovative Medicine excluding COVID-19 Vaccine | |||||||||||||||||||||||||
U.S. |
|
|
| 8.9 |
| 8.9 | - |
|
|
|
| 8.6 |
| 8.6 | - |
| |||||||||
International |
|
|
| 3.2 |
| 8.7 | (5.5 | ) |
|
|
| 4.1 |
| 8.5 | (4.4 | ) | |||||||||
|
|
|
| 6.5 |
| 8.8 | (2.3 | ) |
|
|
| 6.7 |
| 8.6 | (1.9 | ) | |||||||||
| |||||||||||||||||||||||||
MedTech | |||||||||||||||||||||||||
U.S. |
|
|
| 5.7 |
| 5.7 | - |
|
|
|
| 6.2 |
| 6.2 | - |
| |||||||||
International |
|
|
| (1.3 | ) | 3.2 | (4.5 | ) |
|
|
| 0.5 |
| 4.6 | (4.1 | ) | |||||||||
|
|
| 2.2 |
| 4.4 | (2.2 | ) |
|
|
| 3.3 |
| 5.4 | (2.1 | ) | ||||||||||
U.S. |
|
|
| 7.8 |
| 7.8 | - |
|
|
|
| 7.8 |
| 7.8 | - |
| |||||||||
International |
|
|
| 0.2 |
| 5.1 | (4.9 | ) |
|
|
| (1.7 | ) | 2.4 | (4.1 | ) | |||||||||
Worldwide |
|
|
| 4.3 |
| 6.6 | (2.3 | ) |
|
|
| 3.3 |
| 5.2 | (1.9 | ) | |||||||||
U.S. |
|
|
| 7.8 |
| 7.8 | - |
|
|
|
| 7.8 |
| 7.8 | - |
| |||||||||
International |
|
|
| 1.3 |
| 6.4 | (5.1 | ) |
|
|
| 2.7 |
| 6.9 | (4.2 | ) | |||||||||
Worldwide excluding COVID-19 Vaccine |
|
|
| 4.9 |
| % | 7.2 | (2.3 | ) |
|
|
| 5.4 |
| % | 7.4 | (2.0 | ) | |||||||
Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||||||||||||||||||
Refer to supplemental sales information schedules |
(Unaudited; Dollars in Millions) |
|
|
| |||||||||||||||||||||||
|
|
|
| Percent Change |
|
|
|
|
| Percent Change | ||||||||||||||||
|
|
|
| Total |
| Operations |
| Currency |
|
|
|
|
| Total |
| Operations |
| Currency | ||||||||
U.S. |
|
|
| 7.8 |
| % | 7.8 | - |
|
|
|
| 7.8 |
| % | 7.8 |
| - |
| |||||||
Europe |
|
|
| 1.6 |
| 3.4 | (1.8 | ) |
|
|
| (3.2 | ) | (2.4 | ) | (0.8 | ) | |||||||||
Western Hemisphere excluding U.S. |
|
|
| 6.7 |
| 22.6 | (15.9 | ) |
|
|
| 8.8 |
| 21.9 |
| (13.1 | ) | |||||||||
Asia-Pacific, Africa |
|
|
| (4.0 | ) | 1.9 | (5.9 | ) |
|
|
| (2.6 | ) | 3.4 |
| (6.0 | ) | |||||||||
International |
|
|
| 0.2 |
| 5.1 | (4.9 | ) |
|
|
| (1.7 | ) | 2.4 |
| (4.1 | ) | |||||||||
Worldwide |
|
|
| 4.3 |
| % | 6.6 | (2.3 | ) |
|
|
| 3.3 |
| % | 5.2 |
| (1.9 | ) | |||||||
(Unaudited; Dollars in Millions) |
|
|
| |||||||||||||||||||||||
|
|
|
| Percent Change |
|
|
|
|
| Percent Change | ||||||||||||||||
|
|
|
| Total |
| Operations |
| Currency |
|
|
|
|
| Total |
| Operations |
| Currency | ||||||||
U.S.* |
|
|
| 7.8 |
| % | 7.8 | - |
|
|
|
| 7.8 |
| % | 7.8 |
| - |
| |||||||
Europe |
|
|
| 4.1 |
| 6.0 | (1.9 | ) |
|
|
| 5.1 |
| 6.0 |
| (0.9 | ) | |||||||||
Western Hemisphere excluding U.S.* |
|
|
| 6.7 |
| 22.6 | (15.9 | ) |
|
|
| 8.8 |
| 21.9 |
| (13.1 | ) | |||||||||
Asia-Pacific, Africa* |
|
|
| (4.0 | ) | 1.9 | (5.9 | ) |
|
|
| (2.6 | ) | 3.4 |
| (6.0 | ) | |||||||||
International |
|
|
| 1.3 |
| 6.4 | (5.1 | ) |
|
|
| 2.7 |
| 6.9 |
| (4.2 | ) | |||||||||
Worldwide |
|
|
| 4.9 |
| % | 7.2 | (2.3 | ) |
|
|
| 5.4 |
| % | 7.4 |
| (2.0 | ) | |||||||
: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | ||||||||||||||||||||||||||
Refer to supplemental sales information schedules | ||||||||||||||||||||||||||
*No COVID-19 Vaccine sales |
|
|
|
| Percent | ||||||||||||
|
|
|
|
|
|
|
| Increase | ||||||||
|
|
|
|
|
|
|
| (Decrease) | ||||||||
|
|
|
|
|
|
|
|
|
| 4.3 |
| |||||
|
|
|
|
|
|
|
|
|
| 6.3 |
| |||||
|
|
|
|
|
|
|
|
|
| 3.5 |
| |||||
|
|
|
|
|
|
|
|
|
| 5.3 |
| |||||
|
|
|
|
|
|
|
|
|
| (7.1 | ) | |||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| (8.8 | ) | |||||
|
|
|
|
|
|
|
|
|
| 14.2 |
| |||||
|
|
|
|
|
|
|
|
|
| (12.8 | ) | |||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| (5.9 | ) | |||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
| 5.0 |
| |||||
|
|
|
|
|
|
|
|
|
| 1.6 |
| |||||
|
|
|
|
|
| 10.2 |
| |||||||||
|
|
|
|
|
|
|
| |||||||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|
|
| Percent | ||||||||||||
|
|
|
|
|
|
|
| Increase | ||||||||
|
|
|
|
|
|
|
| (Decrease) | ||||||||
|
|
|
|
|
|
|
|
|
| 3.3 |
| |||||
|
|
|
|
|
|
|
|
|
| 1.8 |
| |||||
|
|
|
|
|
|
|
|
|
| 4.1 |
| |||||
|
|
|
|
|
|
|
|
|
| 6.2 |
| |||||
|
|
|
|
|
|
|
|
|
| (2.5 | ) | |||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| 88.5 |
| |||||
|
|
|
|
|
|
|
|
|
| 1,035.1 |
| |||||
|
|
|
|
|
|
|
|
|
| 62.6 |
| |||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| 75.8 |
| |||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
| 4.8 |
| |||||
|
|
|
|
|
|
|
|
|
| 2.7 |
| |||||
|
|
|
|
|
| 11.3 |
| |||||||||
|
|
|
|
|
|
|
| |||||||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|
| ||||||||||
(Dollars in Millions Except Per Share Data) |
|
|
|
|
|
|
| |||||
Net Earnings from Continuing Operations, after tax- as reported |
|
|
|
|
|
|
|
| ||||
Litigation related | 352 |
| 137 |
| 3,078 |
| 7,037 |
| ||||
Intangible Asset Amortization expense | 1,106 |
| 1,130 |
| 2,184 |
| 2,252 |
| ||||
COVID-19 Vaccine related costs | 64 |
| 165 |
| 73 |
| 609 |
| ||||
Restructuring related | (11 | ) | 145 |
| 160 |
| 275 |
| ||||
Medical Device Regulation | 68 |
| 85 |
| 119 |
| 149 |
| ||||
Acquisition, integration and divestiture related | 452 |
| 38 |
| 600 |
| 80 |
| ||||
(Gains)/losses on securities | 431 |
| (1 | ) | 411 |
| 71 |
| ||||
IPR&D impairments | 194 |
| - |
| 194 |
| 49 |
| ||||
Tax impact on special item adjustments | (437 | ) | (307 | ) | (1,293 | ) | (2,287 | ) | ||||
Tax legislation and other tax related | (65 | ) | (38 | ) | (47 | ) | (50 | ) | ||||
Adjusted Net Earnings from Continuing Operations, after tax |
|
|
|
|
|
|
|
| ||||
Average shares outstanding (Diluted) | 2,422.0 |
| 2,625.7 |
| 2,428.5 |
| 2,630.7 |
| ||||
Adjusted net earnings per share from Continuing Operations (Diluted) |
|
|
|
|
|
|
|
| ||||
Operational adjusted net earnings per share from Continuing Operations (Diluted) |
|
|
|
|
| |||||||||||
1 | COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. | ||||||||||
| |||||||||||
2 | In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) and $145 million expense in the fiscal second quarter of 2023 ($275 million Q2 2023 YTD) include asset divestments and the termination of partnered and non-partnered program costs and asset impairments. | ||||||||||
| In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits. | ||||||||||
3 | European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed during 2024. | ||||||||||
4 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. |
|
|
|
|
|
| ||||
U.S. | 8.9 | % | 5.7 | % | 7.8 | % | |||
International | 1.1 | % | (1.3 | )% | 0.2 | % | |||
|
|
|
|
|
| ||||
U.S. |
|
|
|
|
|
| |||
International | (5.3 | ) | (4.5 | ) | (4.9 | ) | |||
|
|
|
|
|
| ||||
U.S. | 8.9 | % | 5.7 | % | 7.8 | % | |||
International | 6.4 | % | 3.2 | % | 5.1 | % | |||
|
|
|
| ||||||
U.S. | (2.0 | ) | (0.7 | ) | |||||
International | 0.0 |
| 0.0 |
| |||||
|
|
|
|
|
| ||||
U.S. | 0.1 |
| 1.0 |
| 0.5 |
| |||
International | 0.2 |
| 0.1 |
| 0.2 |
| |||
|
|
|
|
|
| ||||
U.S. | 9.0 | % | 4.7 | % | 7.6 | % | |||
International | 6.6 | % | 3.3 | % | 5.3 | % | |||
|
|
|
| ||||||
U.S. | 0.0 |
| 0.0 |
| |||||
International | 2.3 |
| 1.3 |
| |||||
|
|
|
|
|
| ||||
U.S. | 9.0 | % | 4.7 | % | 7.6 | % | |||
International | 8.9 | % | 3.3 | % | 6.6 | % | |||
Percentages are based on actual, non-rounded figures and may not sum |
|
|
|
|
|
| ||||
U.S. | 8.6 | % | 6.2 | % | 7.8 | % | |||
International | (3.0 | )% | 0.5 | % | (1.7 | )% | |||
|
|
|
|
|
| ||||
U.S. |
|
|
|
|
|
| |||
International | (4.0 | ) | (4.1 | ) | (4.1 | ) | |||
|
|
|
|
|
| ||||
U.S. | 8.6 | % | 6.2 | % | 7.8 | % | |||
International | 1.0 | % | 4.6 | % | 2.4 | % | |||
|
|
|
| ||||||
U.S. | (1.0 | ) | (0.3 | ) | |||||
International | 0.0 |
| 0.0 |
| |||||
|
|
|
|
|
| ||||
U.S. | 0.1 |
| 0.6 |
| 0.3 |
| |||
International | 0.1 |
| 0.1 |
| 0.1 |
| |||
|
|
|
|
|
| ||||
U.S. | 8.7 | % | 5.8 | % | 7.8 | % | |||
International | 1.1 | % | 4.7 | % | 2.5 | % | |||
|
|
|
| ||||||
U.S. | 0.0 |
| 0.0 |
| |||||
International | 7.5 |
| 4.5 |
| |||||
|
|
|
|
|
| ||||
U.S. | 8.7 | % | 5.8 | % | 7.8 | % | |||
International | 8.6 | % | 4.7 | % | 7.0 | % | |||
Percentages are based on actual, non-rounded figures and may not sum |
|
|
| |||||||||||||||||||||
|
|
|
| ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
US |
|
|
| 4.0 | % | 4.0 | % | - |
|
|
|
| 2.2 | % | 2.2 | % | - |
| |||||
Intl |
|
|
| 6.9 | % | 13.2 | % | -6.3 | % |
|
|
| 7.4 | % | 12.1 | % | -4.7 | % | |||||
WW |
|
|
| 5.0 | % | 7.3 | % | -2.3 | % |
|
|
| 4.2 | % | 6.0 | % | -1.8 | % | |||||
REMICADE | |||||||||||||||||||||||
US |
|
|
| -16.7 | % | -16.7 | % | - |
|
|
|
| -10.1 | % | -10.1 | % | - |
| |||||
US Exports |
|
|
| 7.9 | % | 7.9 | % | - |
|
|
|
| -15.4 | % | -15.4 | % | - |
| |||||
Intl |
|
|
| -16.6 | % | -12.0 | % | -4.6 | % |
|
|
| -16.9 | % | -13.2 | % | -3.7 | % | |||||
WW |
|
|
| -14.9 | % | -13.4 | % | -1.5 | % |
|
|
| -12.9 | % | -11.6 | % | -1.3 | % | |||||
SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||
US |
|
|
| -6.3 | % | -6.3 | % | - |
|
|
|
| -6.2 | % | -6.2 | % | - |
| |||||
Intl |
|
|
| 10.9 | % | 22.8 | % | -11.9 | % |
|
|
| 11.7 | % | 21.3 | % | -9.6 | % | |||||
WW |
|
|
| 1.6 | % | 7.1 | % | -5.5 | % |
|
|
| 2.3 | % | 7.0 | % | -4.7 | % | |||||
STELARA | |||||||||||||||||||||||
US |
|
|
| 2.1 | % | 2.1 | % | - |
|
|
|
| -0.5 | % | -0.5 | % | - |
| |||||
Intl |
|
|
| 5.0 | % | 10.1 | % | -5.1 | % |
|
|
| 5.6 | % | 9.1 | % | -3.5 | % | |||||
WW |
|
|
| 3.1 | % | 4.9 | % | -1.8 | % |
|
|
| 1.8 | % | 3.1 | % | -1.3 | % | |||||
TREMFYA | |||||||||||||||||||||||
US |
|
|
| 30.8 | % | 30.8 | % | - |
|
|
|
| 28.2 | % | 28.2 | % | - |
| |||||
Intl |
|
|
| 23.9 | % | 30.5 | % | -6.6 | % |
|
|
| 25.8 | % | 31.0 | % | -5.2 | % | |||||
WW |
|
|
| 28.3 | % | 30.7 | % | -2.4 | % |
|
|
| 27.3 | % | 29.2 | % | -1.9 | % | |||||
OTHER IMMUNOLOGY | |||||||||||||||||||||||
US |
|
|
| -51.5 | % | -51.5 | % | - |
|
|
|
| -75.4 | % | -75.4 | % | - |
| |||||
Intl |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| |||||
WW |
|
|
| -51.5 | % | -51.5 | % | - |
|
|
|
| -75.4 | % | -75.4 | % | - |
| |||||
US |
|
|
| -15.4 | % | -15.4 | % | - |
|
|
|
| -16.4 | % | -16.4 | % | - |
| |||||
Intl |
|
|
| -13.1 | % | -11.6 | % | -1.5 | % |
|
|
| -41.3 | % | -40.7 | % | -0.6 | % | |||||
WW |
|
|
| -13.9 | % | -12.9 | % | -1.0 | % |
|
|
| -34.0 | % | -33.7 | % | -0.3 | % | |||||
COVID-19 VACCINE | |||||||||||||||||||||||
US |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| |||||
Intl |
|
|
| -39.7 | % | -39.7 | % | 0.0 | % |
|
|
| -80.9 | % | -80.9 | % | 0.0 | % | |||||
WW |
|
|
| -39.7 | % | -39.7 | % | 0.0 | % |
|
|
| -80.9 | % | -80.9 | % | 0.0 | % | |||||
EDURANT / rilpivirine | |||||||||||||||||||||||
US |
|
|
| -2.8 | % | -2.8 | % | - |
|
|
|
| -7.0 | % | -7.0 | % | - |
| |||||
Intl |
|
|
| 11.5 | % | 13.0 | % | -1.5 | % |
|
|
| 14.1 | % | 14.4 | % | -0.3 | % | |||||
WW |
|
|
| 11.0 | % | 12.5 | % | -1.5 | % |
|
|
| 13.4 | % | 13.7 | % | -0.3 | % | |||||
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||
US |
|
|
| -16.0 | % | -16.0 | % | - |
|
|
|
| -16.5 | % | -16.5 | % | - |
| |||||
Intl |
|
|
| 6.5 | % | 9.9 | % | -3.4 | % |
|
|
| 6.0 | % | 7.8 | % | -1.8 | % | |||||
WW |
|
|
| -11.0 | % | -10.3 | % | -0.7 | % |
|
|
| -11.6 | % | -11.2 | % | -0.4 | % | |||||
OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||
US |
|
|
| 18.5 | % | 18.5 | % | - |
|
|
|
| -29.4 | % | -29.4 | % | - |
| |||||
Intl |
|
|
| -25.6 | % | -21.1 | % | -4.5 | % |
|
|
| -29.3 | % | -26.0 | % | -3.3 | % | |||||
WW |
|
|
| -23.1 | % | -18.8 | % | -4.3 | % |
|
|
| -29.3 | % | -26.2 | % | -3.1 | % | |||||
|
|
| |||||||||||||||||||||
|
|
|
| ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
US |
|
|
| 7.1 | % | 7.1 | % | - |
|
|
|
| 7.4 | % | 7.4 | % | - |
| |||||
Intl |
|
|
| -11.1 | % | -6.0 | % | -5.1 | % |
|
|
| -10.2 | % | -5.2 | % | -5.0 | % | |||||
WW |
|
|
| -0.6 | % | 1.5 | % | -2.1 | % |
|
|
| -0.3 | % | 1.9 | % | -2.2 | % | |||||
CONCERTA / Methylphenidate | |||||||||||||||||||||||
US |
|
|
| -47.7 | % | -47.7 | % | - |
|
|
|
| -44.3 | % | -44.3 | % | - |
| |||||
Intl |
|
|
| -9.8 | % | -4.6 | % | -5.2 | % |
|
|
| -5.1 | % | -0.2 | % | -4.9 | % | |||||
WW |
|
|
| -21.5 | % | -17.9 | % | -3.6 | % |
|
|
| -17.8 | % | -14.5 | % | -3.3 | % | |||||
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||
US |
|
|
| 8.8 | % | 8.8 | % | - |
|
|
|
| 8.0 | % | 8.0 | % | - |
| |||||
Intl |
|
|
| -13.1 | % | -9.0 | % | -4.1 | % |
|
|
| -12.4 | % | -8.8 | % | -3.6 | % | |||||
WW |
|
|
| 2.2 | % | 3.5 | % | -1.3 | % |
|
|
| 1.7 | % | 2.8 | % | -1.1 | % | |||||
SPRAVATO | |||||||||||||||||||||||
US |
|
|
| 57.9 | % | 57.9 | % | - |
|
|
|
| 63.9 | % | 63.9 | % | - |
| |||||
Intl |
|
|
| 73.5 | % | 77.4 | % | -3.9 | % |
|
|
| 74.6 | % | 76.3 | % | -1.7 | % | |||||
WW |
|
|
| 60.2 | % | 60.8 | % | -0.6 | % |
|
|
| 65.5 | % | 65.7 | % | -0.2 | % | |||||
OTHER NEUROSCIENCE | |||||||||||||||||||||||
US |
|
|
| -42.5 | % | -42.5 | % | - |
|
|
|
| -37.3 | % | -37.3 | % | - |
| |||||
Intl |
|
|
| -17.0 | % | -10.8 | % | -6.2 | % |
|
|
| -16.2 | % | -9.5 | % | -6.7 | % | |||||
WW |
|
|
| -23.7 | % | -19.1 | % | -4.6 | % |
|
|
| -21.0 | % | -15.8 | % | -5.2 | % | |||||
US |
|
|
| 27.4 | % | 27.4 | % | - |
|
|
|
| 26.8 | % | 26.8 | % | - |
| |||||
Intl |
|
|
| 5.4 | % | 10.8 | % | -5.4 | % |
|
|
| 7.3 | % | 11.7 | % | -4.4 | % | |||||
WW |
|
|
| 15.7 | % | 18.6 | % | -2.9 | % |
|
|
| 16.4 | % | 18.7 | % | -2.3 | % | |||||
CARVYKTI | |||||||||||||||||||||||
US |
|
|
| 46.5 | % | 46.5 | % | - |
|
|
|
| 66.8 | % | 66.8 | % | - |
| |||||
Intl |
|
|
| * | * | * |
|
|
| * | * | * | |||||||||||
WW |
|
|
| 59.8 | % | 59.9 | % | -0.1 | % |
|
|
| 81.5 | % | 81.5 | % | 0.0 | % | |||||
DARZALEX | |||||||||||||||||||||||
US |
|
|
| 24.2 | % | 24.2 | % | - |
|
|
|
| 23.6 | % | 23.6 | % | - |
| |||||
Intl |
|
|
| 11.5 | % | 17.9 | % | -6.4 | % |
|
|
| 12.9 | % | 18.4 | % | -5.5 | % | |||||
WW |
|
|
| 18.4 | % | 21.3 | % | -2.9 | % |
|
|
| 18.6 | % | 21.2 | % | -2.6 | % | |||||
ERLEADA | |||||||||||||||||||||||
US |
|
|
| 32.2 | % | 32.2 | % | - |
|
|
|
| 23.0 | % | 23.0 | % | - |
| |||||
Intl |
|
|
| 28.0 | % | 32.8 | % | -4.8 | % |
|
|
| 32.8 | % | 36.5 | % | -3.7 | % | |||||
WW |
|
|
| 29.8 | % | 32.5 | % | -2.7 | % |
|
|
| 28.4 | % | 30.5 | % | -2.1 | % | |||||
IMBRUVICA | |||||||||||||||||||||||
US |
|
|
| -6.4 | % | -6.4 | % | - |
|
|
|
| -3.9 | % | -3.9 | % | - |
| |||||
Intl |
|
|
| -9.4 | % | -5.6 | % | -3.8 | % |
|
|
| -8.3 | % | -5.6 | % | -2.7 | % | |||||
WW |
|
|
| -8.5 | % | -5.9 | % | -2.6 | % |
|
|
| -6.9 | % | -5.1 | % | -1.8 | % | |||||
TECVAYLI | |||||||||||||||||||||||
US |
|
|
| 27.5 | % | 27.5 | % | - |
|
|
|
| 47.7 | % | 47.7 | % | - |
| |||||
Intl |
|
|
| * | * | * |
|
|
| * | * | * | |||||||||||
WW |
|
|
| 42.9 | % | 43.5 | % | -0.6 | % |
|
|
| 70.2 | % | 70.2 | % | 0.0 | % | |||||
ZYTIGA / abiraterone acetate | |||||||||||||||||||||||
US |
|
|
| 21.6 | % | 21.6 | % | - |
|
|
|
| -19.7 | % | -19.7 | % | - |
| |||||
Intl |
|
|
| -29.6 | % | -23.6 | % | -6.0 | % |
|
|
| -27.2 | % | -22.1 | % | -5.1 | % | |||||
WW |
|
|
| -27.7 | % | -21.9 | % | -5.8 | % |
|
|
| -26.8 | % | -22.0 | % | -4.8 | % | |||||
OTHER ONCOLOGY | |||||||||||||||||||||||
US |
|
|
| * | * | - |
|
|
|
| * | * | - |
| |||||||||
Intl |
|
|
| -10.4 | % | -6.0 | % | -4.4 | % |
|
|
| -8.5 | % | -5.8 | % | -2.7 | % | |||||
WW |
|
|
| 84.2 | % | 87.2 | % | -3.0 | % |
|
|
| 82.4 | % | 84.2 | % | -1.8 | % | |||||
|
| ||||||||||||||||||||||
|
|
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
US |
|
|
| 8.7 | % | 8.7 | % | - |
|
|
|
| 17.5 | % | 17.5 | % | - |
| |||||
Intl |
|
|
| 2.6 | % | 11.2 | % | -8.6 | % |
|
|
| 3.4 | % | 11.0 | % | -7.6 | % | |||||
WW |
|
|
| 6.9 | % | 9.4 | % | -2.5 | % |
|
|
| 13.2 | % | 15.5 | % | -2.3 | % | |||||
OPSUMIT | |||||||||||||||||||||||
US |
|
|
| 13.7 | % | 13.7 | % | - |
|
|
|
| 21.3 | % | 21.3 | % | - |
| |||||
Intl |
|
|
| -5.0 | % | 0.5 | % | -5.5 | % |
|
|
| -2.2 | % | 2.5 | % | -4.7 | % | |||||
WW |
|
|
| 7.1 | % | 9.1 | % | -2.0 | % |
|
|
| 12.7 | % | 14.4 | % | -1.7 | % | |||||
UPTRAVI | |||||||||||||||||||||||
US |
|
|
| 3.3 | % | 3.3 | % | - |
|
|
|
| 15.5 | % | 15.5 | % | - |
| |||||
Intl |
|
|
| 24.6 | % | 34.4 | % | -9.8 | % |
|
|
| 27.6 | % | 36.4 | % | -8.8 | % | |||||
WW |
|
|
| 6.6 | % | 8.1 | % | -1.5 | % |
|
|
| 17.4 | % | 18.7 | % | -1.3 | % | |||||
OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||
US |
|
|
| 18.8 | % | 18.8 | % | - |
|
|
|
| -6.1 | % | -6.1 | % | - |
| |||||
Intl |
|
|
| 3.1 | % | 21.0 | % | -17.9 | % |
|
|
| -6.7 | % | 10.2 | % | -16.9 | % | |||||
WW |
|
|
| 7.2 | % | 20.4 | % | -13.2 | % |
|
|
| -6.5 | % | 5.3 | % | -11.8 | % | |||||
US |
|
|
| -7.7 | % | -7.7 | % | - |
|
|
|
| -9.6 | % | -9.6 | % | - |
| |||||
Intl |
|
|
| 0.6 | % | 4.0 | % | -3.4 | % |
|
|
| -3.6 | % | -1.9 | % | -1.7 | % | |||||
WW |
|
|
| -6.2 | % | -5.5 | % | -0.7 | % |
|
|
| -8.3 | % | -8.0 | % | -0.3 | % | |||||
XARELTO | |||||||||||||||||||||||
US |
|
|
| -7.9 | % | -7.9 | % | - |
|
|
|
| -9.1 | % | -9.1 | % | - |
| |||||
Intl |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| |||||
WW |
|
|
| -7.9 | % | -7.9 | % | - |
|
|
|
| -9.1 | % | -9.1 | % | - |
| |||||
OTHER | |||||||||||||||||||||||
US |
|
|
| -6.4 | % | -6.4 | % | - |
|
|
|
| -11.8 | % | -11.8 | % | - |
| |||||
Intl |
|
|
| 0.6 | % | 4.0 | % | -3.4 | % |
|
|
| -3.6 | % | -1.9 | % | -1.7 | % | |||||
WW |
|
|
| -2.5 | % | -0.6 | % | -1.9 | % |
|
|
| -7.0 | % | -6.0 | % | -1.0 | % | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
See footnotes at end of schedule | |||||||||||||||||||||||
|
| ||||||||||||||||||||||
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
| ||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||
US |
|
|
| 23.3 | % | 23.3 | % | - |
|
|
|
| 21.1 | % | 21.1 | % | - |
| |||||
Intl |
|
|
| 5.7 | % | 11.2 | % | -5.5 | % |
|
|
| 13.4 | % | 18.9 | % | -5.5 | % | |||||
WW |
|
|
| 15.6 | % | 18.0 | % | -2.4 | % |
|
|
| 17.8 | % | 20.2 | % | -2.4 | % | |||||
ELECTROPHYSIOLOGY | |||||||||||||||||||||||
US |
|
|
| 15.7 | % | 15.7 | % | - |
|
|
|
| 18.4 | % | 18.4 | % | - |
| |||||
Intl |
|
|
| 5.4 | % | 11.1 | % | -5.7 | % |
|
|
| 14.6 | % | 20.4 | % | -5.8 | % | |||||
WW |
|
|
| 10.6 | % | 13.4 | % | -2.8 | % |
|
|
| 16.5 | % | 19.4 | % | -2.9 | % | |||||
ABIOMED | |||||||||||||||||||||||
US |
|
|
| 13.2 | % | 13.2 | % | - |
|
|
|
| 14.1 | % | 14.1 | % | - |
| |||||
Intl |
|
|
| 20.7 | % | 25.3 | % | -4.6 | % |
|
|
| 16.5 | % | 20.0 | % | -3.5 | % | |||||
WW |
|
|
| 14.5 | % | 15.4 | % | -0.9 | % |
|
|
| 14.5 | % | 15.2 | % | -0.7 | % | |||||
SHOCKWAVE | |||||||||||||||||||||||
US |
|
|
| * | * | - |
|
|
|
| * | * | - |
| |||||||||
Intl |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| |||||
WW |
|
|
| * | * | - |
|
|
|
| * | * | - |
| |||||||||
OTHER CARDIOVASCULAR | |||||||||||||||||||||||
US |
|
|
| 12.5 | % | 12.5 | % | - |
|
|
|
| 7.7 | % | 7.7 | % | - |
| |||||
Intl |
|
|
| -4.5 | % | -1.0 | % | -3.5 | % |
|
|
| 0.8 | % | 4.8 | % | -4.0 | % | |||||
WW |
|
|
| 0.3 | % | 2.8 | % | -2.5 | % |
|
|
| 2.9 | % | 5.7 | % | -2.8 | % | |||||
US |
|
|
| 2.5 | % | 2.5 | % | - |
|
|
|
| 4.3 | % | 4.3 | % | - |
| |||||
Intl |
|
|
| 1.4 | % | 4.5 | % | -3.1 | % |
|
|
| 1.3 | % | 3.6 | % | -2.3 | % | |||||
WW |
|
|
| 2.1 | % | 3.3 | % | -1.2 | % |
|
|
| 3.2 | % | 4.0 | % | -0.8 | % | |||||
HIPS | |||||||||||||||||||||||
US |
|
|
| 5.8 | % | 5.8 | % | - |
|
|
|
| 8.9 | % | 8.9 | % | - |
| |||||
Intl |
|
|
| 3.4 | % | 6.8 | % | -3.4 | % |
|
|
| 2.6 | % | 5.0 | % | -2.4 | % | |||||
WW |
|
|
| 4.9 | % | 6.2 | % | -1.3 | % |
|
|
| 6.5 | % | 7.4 | % | -0.9 | % | |||||
KNEES | |||||||||||||||||||||||
US |
|
|
| 4.2 | % | 4.2 | % | - |
|
|
|
| 5.5 | % | 5.5 | % | - |
| |||||
Intl |
|
|
| 14.9 | % | 17.7 | % | -2.8 | % |
|
|
| 13.6 | % | 15.4 | % | -1.8 | % | |||||
WW |
|
|
| 8.4 | % | 9.5 | % | -1.1 | % |
|
|
| 8.7 | % | 9.4 | % | -0.7 | % | |||||
TRAUMA | |||||||||||||||||||||||
US |
|
|
| 3.0 | % | 3.0 | % | - |
|
|
|
| 2.9 | % | 2.9 | % | - |
| |||||
Intl |
|
|
| 2.4 | % | 5.5 | % | -3.1 | % |
|
|
| 0.0 | % | 2.1 | % | -2.1 | % | |||||
WW |
|
|
| 2.8 | % | 3.8 | % | -1.0 | % |
|
|
| 1.9 | % | 2.6 | % | -0.7 | % | |||||
SPINE, SPORTS & OTHER | |||||||||||||||||||||||
US |
|
|
| -0.8 | % | -0.8 | % | - |
|
|
|
| 2.7 | % | 2.7 | % | - |
| |||||
Intl |
|
|
| -6.1 | % | -2.9 | % | -3.2 | % |
|
|
| -3.5 | % | -1.0 | % | -2.5 | % | |||||
WW |
|
|
| -3.1 | % | -1.7 | % | -1.4 | % |
|
|
| 0.0 | % | 1.1 | % | -1.1 | % | |||||
|
| ||||||||||||||||||||||
|
|
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
US |
|
|
| -2.0 | % | -2.0 | % | - |
|
|
|
| -0.4 | % | -0.4 | % | - |
| |||||
Intl |
|
|
| -5.5 | % | -0.7 | % | -4.8 | % |
|
|
| -3.8 | % | 0.7 | % | -4.5 | % | |||||
WW |
|
|
| -4.1 | % | -1.2 | % | -2.9 | % |
|
|
| -2.5 | % | 0.3 | % | -2.8 | % | |||||
ADVANCED | |||||||||||||||||||||||
US |
|
|
| 0.1 | % | 0.1 | % | - |
|
|
|
| 0.2 | % | 0.2 | % | - |
| |||||
Intl |
|
|
| -10.8 | % | -6.4 | % | -4.4 | % |
|
|
| -8.0 | % | -3.7 | % | -4.3 | % | |||||
WW |
|
|
| -6.7 | % | -3.9 | % | -2.8 | % |
|
|
| -4.8 | % | -2.2 | % | -2.6 | % | |||||
GENERAL | |||||||||||||||||||||||
US |
|
|
| -3.7 | % | -3.7 | % | - |
|
|
|
| -0.9 | % | -0.9 | % | - |
| |||||
Intl |
|
|
| -0.7 | % | 4.5 | % | -5.2 | % |
|
|
| -0.2 | % | 4.7 | % | -4.9 | % | |||||
WW |
|
|
| -1.9 | % | 1.2 | % | -3.1 | % |
|
|
| -0.5 | % | 2.4 | % | -2.9 | % | |||||
US |
|
|
| -1.2 | % | -1.2 | % | - |
|
|
|
| -1.5 | % | -1.5 | % | - |
| |||||
Intl |
|
|
| -2.0 | % | 2.2 | % | -4.2 | % |
|
|
| -3.2 | % | 0.6 | % | -3.8 | % | |||||
WW |
|
|
| -1.7 | % | 0.8 | % | -2.5 | % |
|
|
| -2.5 | % | -0.3 | % | -2.2 | % | |||||
CONTACT LENSES / OTHER | |||||||||||||||||||||||
US |
|
|
| 0.2 | % | 0.2 | % | - |
|
|
|
| -0.6 | % | -0.6 | % | - |
| |||||
Intl |
|
|
| -4.0 | % | 1.2 | % | -5.2 | % |
|
|
| -5.6 | % | -0.9 | % | -4.7 | % | |||||
WW |
|
|
| -2.2 | % | 0.7 | % | -2.9 | % |
|
|
| -3.4 | % | -0.8 | % | -2.6 | % | |||||
SURGICAL | |||||||||||||||||||||||
US |
|
|
| -5.8 | % | -5.8 | % | - |
|
|
|
| -4.8 | % | -4.8 | % | - |
| |||||
Intl |
|
|
| 2.1 | % | 4.5 | % | -2.4 | % |
|
|
| 2.1 | % | 4.0 | % | -1.9 | % | |||||
WW |
|
|
| -0.5 | % | 1.2 | % | -1.7 | % |
|
|
| -0.1 | % | 1.1 | % | -1.2 | % | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, |
therefore, may not recalculate precisely |
* Percentage greater than 100% or not meaningful |
(1) Operational growth excludes the effect of translational currency |
(2) Unaudited |
(3) Reported as U.S. sales |
(4) Previously referred to as Interventional Solutions |
(5) Acquired on May 31, 2024 |
(Dollars in Millions) | ||||||||||||||||||||||||||||||||
|
|
| ||||||||||||||||||||||||||||||
|
|
|
|
| Percent Change |
|
|
|
|
|
|
| Percent Change |
| ||||||||||||||||||
|
|
|
|
| Total |
| Operations |
| Currency |
|
|
|
|
|
|
| Total |
| Operations |
| Currency | |||||||||||
Innovative Medicine | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| 8.9 |
|
| 8.9 |
| - |
|
|
|
| 8.6 |
|
| 8.6 |
| - |
| ||||||||||||
International |
|
|
| 1.1 |
| 6.4 |
| (5.3 | ) |
|
|
| (3.0 | ) | 1.0 |
| (4.0 | ) | ||||||||||||||
Worldwide |
|
|
| 5.5 |
| 7.8 |
| (2.3 | ) |
|
|
| 3.3 |
| 5.2 |
| (1.9 | ) | ||||||||||||||
COVID-19 Vaccine | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| ||||||||||||||
International |
|
|
| (39.7 | ) | (39.7 | ) | 0.0 |
|
|
|
| (80.9 | ) | (80.9 | ) | 0.0 |
| ||||||||||||||
Worldwide |
|
|
| (39.7 | ) | (39.7 | ) | 0.0 |
|
|
|
| (80.9 | ) | (80.9 | ) | 0.0 |
| ||||||||||||||
Innovative Medicine excluding COVID-19 Vaccine | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| 8.9 |
| 8.9 |
| - |
|
|
|
| 8.6 |
| 8.6 |
| - |
| ||||||||||||||
International |
|
|
| 3.2 |
| 8.7 |
| (5.5 | ) |
|
|
| 4.1 |
| 8.5 |
| (4.4 | ) | ||||||||||||||
Worldwide |
|
|
| 6.5 |
| 8.8 |
| (2.3 | ) |
|
|
| 6.7 |
| 8.6 |
| (1.9 | ) | ||||||||||||||
Worldwide | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| 7.8 |
| 7.8 |
| - |
|
|
|
| 7.8 |
| 7.8 |
| - |
| ||||||||||||||
International |
|
|
| 0.2 |
| 5.1 |
| (4.9 | ) |
|
|
| (1.7 | ) | 2.4 |
| (4.1 | ) | ||||||||||||||
Worldwide |
|
|
| 4.3 |
| 6.6 |
| (2.3 | ) |
|
|
| 3.3 |
| 5.2 |
| (1.9 | ) | ||||||||||||||
COVID-19 Vaccine | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| - |
| - |
| - |
|
|
|
| - |
| - |
| - |
| ||||||||||||||
International |
|
|
| (39.7 | ) | (39.7 | ) | 0.0 |
|
|
|
| (80.9 | ) | (80.9 | ) | 0.0 |
| ||||||||||||||
Worldwide |
|
|
| (39.7 | ) | (39.7 | ) | 0.0 |
|
|
|
| (80.9 | ) | (80.9 | ) | 0.0 |
| ||||||||||||||
Worldwide | ||||||||||||||||||||||||||||||||
U.S. |
|
|
| 7.8 |
| 7.8 |
| - |
|
|
|
| 7.8 |
| 7.8 |
| - |
| ||||||||||||||
International |
|
|
| 1.3 |
| 6.4 |
| (5.1 | ) |
|
|
| 2.7 |
| 6.9 |
| (4.2 | ) | ||||||||||||||
Worldwide excluding COVID-19 Vaccine |
|
|
| 4.9 |
|
| 7.2 |
| (2.3 | ) |
|
|
| 5.4 |
|
| 7.4 |
| (2.0 | ) | ||||||||||||
Europe |
|
|
| 1.6 |
|
| 3.4 |
| (1.8 | ) |
|
|
| (3.2 | ) |
| (2.4 | ) | (0.8 | ) | ||||||||||||
Europe COVID-19 Vaccine Sales |
|
|
| (39.7 | ) | (39.7 | ) | 0.0 |
|
|
|
| (80.9 | ) | (80.9 | ) | 0.0 |
| ||||||||||||||
Europe excluding COVID-19 Vaccine Sales |
|
|
| 4.1 |
|
| 6.0 |
| (1.9 | ) |
|
|
| 5.1 |
|
| 6.0 |
| (0.9 | ) |
Johnson & Johnson and Subsidiaries | ||||||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||||||||||
Q2 QTD - Income Before Tax and Research & Development Expense by Segment | ||||||||||||||||||||||||||
Dollars in Millions | ||||||||||||||||||||||||||
Innovative Medicine |
| MedTech |
| Unallocated |
|
| Worldwide Total | |||||||||||||||||||
2024 | 2023 | 2024 | 2023 |
| 2024 | 2023 |
|
| 2024 | 2023 | ||||||||||||||||
Reported Income Before Tax by Segment From Continuing Operations | $ | 5,459 |
| 4,812 |
| 1,089 |
| 1,671 |
| (800 | ) | (177 | ) | 5,748 |
| 6,306 |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
Intangible asset amortization expense | 694 |
| 748 |
| 412 |
| 382 |
| - |
| - |
| 1,106 |
| 1,130 |
| ||||||||||
In-process research and development impairments | 194 |
| - |
| - |
| - |
| - |
| - |
| 194 |
| - |
| ||||||||||
Litigation related | 43 |
| (93 | ) | (4 | ) | 60 |
| 313 |
| 170 |
| 352 |
| 137 |
| ||||||||||
Loss/(gain) on securities | 70 |
| 38 |
| 22 |
| (39 | ) | 339 |
| - |
| 431 |
| (1 | ) | ||||||||||
Restructuring related | (63 | ) | 145 |
| 52 |
| - |
| - |
| - |
| (11 | ) | 145 |
| ||||||||||
Acquisition, integration and divestiture related | 1 |
| - |
| 409 |
| 38 |
| 42 |
| - |
| 452 |
| 38 |
| ||||||||||
Medical Device Regulation | - |
| - |
| 68 |
| 85 |
| - |
| - |
| 68 |
| 85 |
| ||||||||||
COVID-19 Vaccine related costs | 64 |
| 165 |
| - |
| - |
| - |
| - |
| 64 |
| 165 |
| ||||||||||
Adjusted Income Before Tax by Segment From Continuing Operations | $ | 6,462 |
| 5,815 |
| 2,048 |
| 2,197 |
| (106 | ) | (7 | ) | 8,404 |
| 8,005 |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
Estimated as of 7/17/2024 | ||||||||||||||||||||||||||
As Reported Research and development expense | $ | 2,722 |
| 3,048 |
| 718 |
| 655 |
| 3,440 |
| 3,703 |
| |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Johnson & Johnson and Subsidiaries | ||||||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||||||||||
Q2 YTD - Income Before Tax and Research & Development Expense by Segment | ||||||||||||||||||||||||||
Dollars in Millions | ||||||||||||||||||||||||||
Innovative Medicine |
| MedTech |
| Unallocated |
|
| Worldwide Total | |||||||||||||||||||
2024 | 2023 | 2024 | 2023 |
| 2024 | 2023 |
|
| 2024 | 2023 | ||||||||||||||||
Reported Income Before Tax by Segment From Continuing Operations | $ | 10,428 |
| 9,214 |
| 2,609 |
| 3,080 |
| (3,575 | ) | (7,275 | ) | 9,462 |
| 5,019 |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
Intangible asset amortization expense | 1,392 |
| 1,487 |
| 792 |
| 765 |
| - |
| - |
| 2,184 |
| 2,252 |
| ||||||||||
In-process research and development impairments | 194 |
| - |
| - |
| 49 |
| - |
| - |
| 194 |
| 49 |
| ||||||||||
Litigation related | 43 |
| (93 | ) | (4 | ) | 60 |
| 3,039 |
| 7,070 |
| 3,078 |
| 7,037 |
| ||||||||||
Loss/(gain) on securities | 15 |
| 76 |
| 44 |
| (5 | ) | 352 |
| - |
| 411 |
| 71 |
| ||||||||||
Restructuring related | 81 |
| 275 |
| 79 |
| - |
| - |
| - |
| 160 |
| 275 |
| ||||||||||
Acquisition, integration and divestiture related | 48 |
| - |
| 470 |
| 80 |
| 82 |
| - |
| 600 |
| 80 |
| ||||||||||
Medical Device Regulation | - |
| - |
| 119 |
| 149 |
| - |
| - |
| 119 |
| 149 |
| ||||||||||
COVID-19 Vaccine related costs | 73 |
| 609 |
| - |
| - |
| - |
| - |
| 73 |
| 609 |
| ||||||||||
Adjusted Income Before Tax by Segment From Continuing Operations | $ | 12,274 |
| 11,568 |
| 4,109 |
| 4,178 |
| (102 | ) | (205 | ) | 16,281 |
| 15,541 |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
Estimated as of 7/17/2024 | ||||||||||||||||||||||||||
As Reported Research and development expense | $ | 5,618 |
| 5,826 |
| 1,364 |
| 1,332 |
| 6,982 |
| 7,158 |
| |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold | $ | 6,869 |
| (1,106 | ) | (2 | ) | (50 | ) | (30 | ) | (4 | ) | - |
| 5,677 |
| |||||||||||||||||
Selling, marketing and admin expenses |
| 5,681 |
| (5 | ) | 5,676 |
| |||||||||||||||||||||||||||
Research and development expense |
| 3,440 |
| (15 | ) | (33 | ) | (10 | ) | 3,382 |
| |||||||||||||||||||||||
Other (Income) / Expense |
| 653 |
| - |
| (352 | ) | - |
| (387 | ) | (431 | ) | (50 | ) | (567 | ) | |||||||||||||||||
In-process research and development impairments |
| 194 |
| (194 | ) | - |
| - |
| |||||||||||||||||||||||||
Restructuring |
| (13 | ) | 13 |
| - |
| |||||||||||||||||||||||||||
Provision for taxes on income |
| 1,062 |
| 156 |
| 70 |
| 43 |
| (6 | ) | 125 |
| 21 |
| 14 |
| 14 |
| 65 |
| 1,564 |
| |||||||||||
Net Earnings from Continuing Operations |
| 4,686 |
| 950 |
| 282 |
| 151 |
| (5 | ) | 327 |
| 410 |
| 54 |
| 50 |
| (65 | ) | 6,840 |
| |||||||||||
Cost of products sold | $ | 6,462 |
| (1,130 | ) | - |
| (34 | ) | 38 |
| - |
| 5,336 |
| |||||||||||||||||||
Selling, marketing and admin expenses |
| 5,396 |
| (8 | ) | 5,388 |
| |||||||||||||||||||||||||||
Research and development expense |
| 3,703 |
| - |
| (44 | ) | (46 | ) | 3,613 |
| |||||||||||||||||||||||
Other (Income) / Expense |
| (384 | ) | - |
| (137 | ) | - |
| (38 | ) | 1 |
| (156 | ) | (714 | ) | |||||||||||||||||
In-process research and development impairments |
| - |
| - |
| - |
| |||||||||||||||||||||||||||
Restructuring |
| 145 |
| (145 | ) | - |
| |||||||||||||||||||||||||||
Provision for taxes on income |
| 930 |
| 177 |
| 29 |
| - |
| 37 |
| 12 |
| (1 | ) | 15 |
| 38 |
| 38 |
| 1,275 |
| |||||||||||
Net Earnings from Continuing Operations |
| 5,376 |
| 953 |
| 108 |
| - |
| 108 |
| 26 |
| - |
| 71 |
| 126 |
| (38 | ) | 6,730 |
| |||||||||||
Cost of products sold | $ | 13,380 |
| (2,184 | ) | (9 | ) | (50 | ) | (50 | ) | (6 | ) | 11,081 |
| |||||||||||||||||||
Selling, marketing and admin expenses |
| 10,938 |
| (9 | ) | - |
| 10,929 |
| |||||||||||||||||||||||||
Research and development expense |
| 6,982 |
| (33 | ) | (60 | ) | (17 | ) | 6,872 |
| |||||||||||||||||||||||
Other (Income) / Expense |
| 3,057 |
| - |
| (3,078 | ) | - |
| (517 | ) | (411 | ) | (50 | ) | (999 | ) | |||||||||||||||||
In-process research and development impairments |
| 194 |
| (194 | ) | - |
| - |
| - |
| - |
| - |
| |||||||||||||||||||
Restructuring |
| 151 |
| (151 | ) | - |
| |||||||||||||||||||||||||||
Provision for taxes on income |
| 1,521 |
| 304 |
| 697 |
| 43 |
| 33 |
| 163 |
| 14 |
| 23 |
| 16 |
| 47 |
| 2,861 |
| |||||||||||
Net Earnings from Continuing Operations |
| 7,941 |
| 1,880 |
| 2,381 |
| 151 |
| 127 |
| 437 |
| 397 |
| 96 |
| 57 |
| (47 | ) | 13,420 |
| |||||||||||
Cost of products sold | $ | 13,149 |
| (2,248 | ) | - |
| (57 | ) | (168 | ) | 10,676 |
| |||||||||||||||||||||
Selling, marketing and admin expenses |
| 10,302 |
| (15 | ) | 10,287 |
| |||||||||||||||||||||||||||
Research and development expense |
| 7,158 |
| (16 | ) | (78 | ) | (62 | ) | 7,002 |
| |||||||||||||||||||||||
Other (Income) / Expense |
| 6,556 |
| (4 | ) | (7,037 | ) | - |
| (64 | ) | (71 | ) | (378 | ) | (998 | ) | |||||||||||||||||
In-process research and development impairments |
| 49 |
| (49 | ) | - |
| - |
| |||||||||||||||||||||||||
Restructuring |
| 275 |
| (275 | ) | - |
| |||||||||||||||||||||||||||
Provision for taxes on income |
| 134 |
| 354 |
| 1,651 |
| 11 |
| 69 |
| 17 |
| 15 |
| 27 |
| 143 |
| 50 |
| 2,471 |
| |||||||||||
Net Earnings from Continuing Operations |
| 4,885 |
| 1,898 |
| 5,386 |
| 38 |
| 206 |
| 63 |
| 56 |
| 123 |
| 465 |
| (50 | ) | 13,070 |
|
Media contact: Tesia Williams [email protected]
Investor contact: Jessica Moore [email protected]
Multimedia Files:
Contact Investor Relations
Questions please contact us:.
![](http://farmaciacoslada.online/777/templates/cheerup1/res/banner1.gif)
COMMENTS
Download our Coronavirus Google Slides themes and PowerPoint templates to create informative presentations Free Easy to edit Professional. Got any suggestions? We want to hear from you! Send us a message and help improve Slidesgo ... The COVID-19 vaccine has improved the pandemic situation. We are gradually returning to our pre-COVID-19 lifestyle.
Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations. 15. Coronavirus PowerPoint Template. Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection.
PK !$ƽƴ [! [Content_Types].xml ¢ ( Ìšßn›0 Æï'í · 8t[×NIªi ®¶µR» pá ° ma'MÞ~ '"V$ [ÎM ƒÏw~6øøƒd|³*ro ¥Ì8›øQ8ò=`1O26›ø ~ W¾' e Í9ƒ‰¿ éßLß¾ ?¬ HOG39ñçJ‰Ï„Èx •! Àô™"— UºYΈ ñ?: r1 ]'˜3 L ªÒð§ão ÒE®¼ï+}¸!I™J¨¢¾÷µé[¥›øTˆ‹©Ò]È*Hù¦ é"ø+`ö*>+*†úDwŒ`Ý!Õñîˆ ry€rÉ'WÓ l¦"Ô ...
The best way to prevent and slow down transmission is be well informed about the COVID-19 virus, the disease it causes and how it spreads. Protect yourself and others from infection by washing your hands frequently and not touching your face, stay home if you're sick, avoid close contact with people, do social distancing and self quarantine.
PK !aŽF | 'u [Content_Types].xml ¢ ( Ì ]oÛ6 †ï ì? º lI--ÉEœbh7`À¶ h ì-'h[¾&ÑNòïGÉ uR%-|Èò½ ¢ >'È÷% éæíC-Žv¼ª""_ZîÄ ...
If a patient tests negative by Rapid Antigen Test (RAT) FDA recommends. If symptomatic, test at least twice 48 hours apart. A third test might be needed if the patient is concerned they have COVID-19. If asymptomatic, but believe they have been exposed, test with RAT at least 3 times, each 48 hours apart to be considered truly negative.
PK !mú !^ 89 [Content_Types].xml ¢ ( Ì›mo›0 ÇßOÚw@¼ ÂCºnjZM{ &m]¥v ÀƒK ¶… ´ùö3 ´´"Ou¬»7Q ÜÝωóÿ‡«¹¸z( o •Ê Ÿøápä{ÀS'å|6ñ ß} œûžÒŒg¬ &þ " uùöÍÅÝJ‚òL4W ®µü * CÉÔPHàæÌTT%ÓfXÍ ÉÒ l A4 ©à ¸ è:‡ yñ ¦lQhïëƒ9Ü'ü•0ó½Ïí…u‰Ÿ—u‚æDÐ #y H}¼?¢‚B½ aR yÊ´9 ,yöb.ƒõ†&²¹FÍs©Þ ...
PK !ä 'ºC í0 [Content_Types].xml ¢ ( Ì›ßo›0 Çß'í @¼N n]75¦ý &m]¥vÒ^=¸$ÞÀ¶°"6ÿý $)hCzöŽ—( ßÝ Ç|}¾º§ç·E ¬ Ô\Ši 'a"• óiøóúËè$ ´a"c¹ 0 × Ãó³—/N¯× t`…ž† cÔû(Òé ¦ÇR °wf²,˜±—å ßÚæ†dÎgað±éW…š†¼¨ì«ö¨Óâ ‚y§I}ã1›ƒM"è6©Ú»-JÈõ ¦TÎSfìýh%² 6Ú ÖØZÖ}ô‚+ýÊvx$‚^u3Ùö'¬ª ...
A COVID 19 PowerPoint template is a ready-made presentation template that provides a structured framework for creating professional COVID 19 presentations. The COVID 19 PPT presentation template includes design elements, layouts, and fonts that you can customize to fit your content and brand.
COVID-19. CDC Clinician Outreach Call - August 12, 2021. John Farley, MD, MPH Director, Office of Infectious Diseases, Office of New Drugs, CDER. Casirivimab and imdevimab are recombinant human IgG1 monoclonal antibodies that target the receptor binding domain of the spike protein of SARS-CoV-2.
Tool 4. Presentation template - 28 April 2021. 28 April 2021. | COVID-19: Critical preparedness, readiness and response. Download (3.8 MB)
The clinical presentation of COVID-19 ranges from asymptomatic to critical illness. An infected person can transmit SARS-CoV-2, the virus that causes COVID-19, before the onset of symptoms. Symptoms can change over the course of illness and can progress in severity. Uncommon presentations of COVID-19 can occur, might vary by the age of the ...
Download the Free COVID-19 Impact PowerPoint presentation to share with your senior management and customers. COVID-19 has impacted businesses massively. Many of us are at a point in reviewing what it all means in the short and long run. To help you build business reviews and have key discussions, we have created a PowerPoint presentation for ...
Coronavirus disease 2019 or COVID-19 is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a new. coronavirus first identified during an investigation into an outbreak in Wuhan, Hubei Province, China. Initial case-patients reported visiting a large seafood and live animal market in Wuhan.
Covid-19 PPT Template: Download our free Coronavirus Impact PowerPoint Template with amazing design to create informative presentations. These covid19 ppt templates are 100% editable, totally customized, easily downloadable, and ready to use.
On January 31, 2022: FDA approved the Moderna COVID-19 vaccine (Spikevax) for individuals 18 years of age and older. Spikevax biologics license application (BLA) builds upon the data and information that supported the EUA, such as preclinical and clinical data, as well as details of the manufacturing process and sites where the vaccine is made.
CrystalGraphics creates templates designed to make even average presentations look incredible. Below you'll see thumbnail sized previews of the title slides of a few of our 171 best corona virus templates for PowerPoint and Google Slides. ... Slide set featuring coronavirus covid-19 coronavirus disease 2019 a doctor holds his hand out with ...
PowerPoint Presentation. Training on Operational Microplanning for COVID-19 Vaccination. Step 5: Plan service delivery. For more information, see WHO's Guidance on Operational Microplanning for COVID-19 Vaccination (2023), available at who.int/publications. 2 May 2023.
Below you'll see thumbnail sized previews of the title slides of a few of our 236 best coronavirus templates for PowerPoint and Google Slides. The text you'll see in in those slides is just example text. The coronavirus-related image or video you'll see in the background of each title slide is designed to help you set the stage for your ...
221 Best Covid-Themed Templates. CrystalGraphics creates templates designed to make even average presentations look incredible. Below you'll see thumbnail sized previews of the title slides of a few of our 221 best covid templates for PowerPoint and Google Slides. The text you'll see in in those slides is just example text.
Pulmonary function and 6-minute walk test distance results among COVID-19 hospitalized patients 56%. 6 minute walk test distance <LLN DLCO <80% predicted. Not requiring supplemental oxygen Requiring supplemental oxygen Requiring HFNC, NIV, or IMV. LLN = lower limit of normal; DLCO = diffusion capacity for carbon monoxide.
Since the start of the COVID-19 pandemic, however, Dutch public health policy has centred around a linear conception of COVID-19 illness, emphasising a brief acute symptomatic phase followed by recovery within 14 days of the onset of symptoms and a clear distinction between acute and recovered states (Ajbar et al., Citation 2021). Following ...
Presentations and Indications. COMIRNATY (30 mcg/0.3mL glass pre-filled syringe presentation) is indicated for individuals 12 years of age and older. Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) ...
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* Significant new product pipeline ...
Daily number of COVID-19 death reported to CDC and 7-day cumulative incidence rate (per 100,000 Population), United States, Jan. 2020-May 2021. Total deaths in the US: 587,342. 7-Day Moving Average: 500. Blue bars — number of daily deaths.